

RESULT 1	AX301999	1362 bp	DNA	linear	PAT 30-NOV-2001
LOCUS	AX301999				
DEFINITION	Sequence 3 from Patent WO0174900.				
ACCESSION	AX301999				
VERSION	AX301999.1	GI:17382987			
KEYWORDS					
SOURCE					
ORGANISM	Homo sapiens (human)				
	Homo sapiens				
	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
REFERENCE	1				
AUTHORS	Kaplow, J., Haws, T., Rosier, M. and Benefle, P.				
TITLE	Nuclear factor kb inducing factor				
JOURNAL	Patent: WO 0174900-A 3 11-OCT-2001;				
	Aventis Pharmaceuticals Products Inc. (US)				
FEATURES	location/Qualifiers				
source	1..1362				
	/organism="Homo sapiens"				
	/mol_type="unassigned DNA"				
	/db_xref="taxon:9606"				
ORIGIN					
Query Match	100.0 %;	Score 1362;	DB 6;	Length 1362;	
Best Local Similarity	100.0 %;	Pred. No. 0;			
Matches 1362;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
QY	1 ATGGCGCTGGTGGCGCGACCTGTTGCTGCTGCTGCTGACTGCTGGCACTGCGGCTCCGGC	60			
Db	1 ATGGCGCTGGTGGCGCGACCTGTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCGGC	60			
QY	61 CTGGGGCTGGCCGGTGGGGCCCGACGGGGGAGAAATCTCTCCGGGGATGAGACAGTTT	120			
Db	61 CTGGGGCTGGCCGGTGGGGCCCGACGGGGGAGAAATCTCTCCGGGGATGAGACAGTTT	120			
QY	121 TGGCATGTGACTGACTTACACTTACACTTACACTTACACTTACACTTACACTTACACTTACACTT	180			
Db	121 TGGCATGTGACTGACTTACACTTACACTTACACTTACACTTACACTTACACTTACACTTACACTT	180			
QY	181 GTGTGTCCTTCATTAAGGTGCAAAAGGCTCCCAACCTGGCCCTTTTGAGATGTTCTG	240			
Db	181 GTGTGTCCTTCATTAAGGTGCAAAAGGCTCCCAACCTGGCCCTTTTGAGATGTTCTG	240			

QY 241 TGTGATTCCTCATATCAACTTATTTTGTGAGCAATTTGATTTTATTAATAATCGGACAA 300
 DB 241 TGTGATTCCTCATATCAACTTATTTTGTGAGCAATTTGATTTTATTAATAATCGGACAA 300
 QY 301 GAAGCAATCTTTCATGATATGAGCAAGGGATAGCCCACTGATCTCTGACTGAATCTC 360
 DB 301 GAAGCAATCTTTCATGATATGAGCAAGGGATAGCCCACTGATCTCTGACTGAATCTC 360
 QY 361 TCAACAGACACTGTATTAATGTGATACATAATATGACAAACCACTCCAGAGTCTCTT 420
 DB 361 TCAACAGACACTGTATTAATGTGATACATAATATGACAAACCACTCCAGAGTCTCTT 420
 QY 421 CCAATCTCCAGGTTTTCCCTGGCGGGGTATCATGACTATTTGGCCAGAGATCAATG 480
 DB 421 CCAATCTCCAGGTTTTCCCTGGCGGGGTATCATGACTATTTGGCCAGAGATCAATG 480
 QY 481 TCTGTATGCCAGTAAAGTGTACAAATGACAGTACAACTCTGGAATCCATGGCTAGAT 540
 DB 481 TCTGTATGCCAGTAAAGTGTACAAATGACAGTACAACTCTGGAATCCATGGCTAGAT 540
 QY 541 GAAGAACTATTTAGTACTTTAAGAAAGGTGTTTTTATTCACAGAAAGTTACACTAAT 600
 DB 541 GAAGAACTATTTAGTACTTTAAGAAAGGTGTTTTTATTCACAGAAAGTTACACTAAT 600
 QY 601 CCAAACTTAGATCATCATGCTAAACAACTTGATACAGGCCCCCAATATATATGACA 660
 DB 601 CCAAACTTAGATCATCATGCTAAACAACTTGATACAGGCCCCCAATATATATGACA 660
 QY 661 CTGAACAGACTGACCCAGCCCAACCACTTTGAATGGCTAGAAAGTACATTTGAACACTCT 720
 DB 661 CTGAACAGACTGACCCAGCCCAACCACTTTGAATGGCTAGAAAGTACATTTGAACACTCT 720
 QY 721 CAGCAGATATAGAGAAAGGTATATATATGACATATGCTTCCAGTGGGGTATCTGCCATCT 780
 DB 721 CAGCAGATATAGAGAAAGGTATATATATGACATATGCTTCCAGTGGGGTATCTGCCATCT 780
 QY 781 TCACAGAACTACACAGATGAGAAATCATATATGAGAAATTTGATATTTTTCAA 840
 DB 781 TCACAGAACTACACAGATGAGAAATCATATATGAGAAATTTGATATTTTTCAA 840
 QY 841 AAATACAGTATGTCATTTGAGAGCAATTTTATGACACACTCAGAGACAGACATATATG 900
 DB 841 AAATACAGTATGTCATTTGAGAGCAATTTTATGACACACTCAGAGACAGACATATATG 900
 QY 901 GTTCTTTCAGATTAATAAAGAGAGTCCAGTAAATTTCTTTGTGGCTCTGCTGTTACA 960
 DB 901 GTTCTTTCAGATTAATAAAGAGAGTCCAGTAAATTTCTTTGTGGCTCTGCTGTTACA 960
 QY 961 CCAAGTAAAGTGTATTTAGAAAAAGAGCAACCAATCTGCTGATCAGACTGTTTCAGTAT 1020
 DB 961 CCAAGTAAAGTGTATTTAGAAAAAGAGCAACCAATCTGCTGATCAGACTGTTTCAGTAT 1020
 QY 1021 GATCTCTGTATTAATAATTTATGATATGTTGAGATTTACTGTAATCTGACAGAGGCG 1080
 DB 1021 GATCTCTGTATTAATAATTTATGATATGTTGAGATTTACTGTAATCTGACAGAGGCG 1080
 QY 1081 AATCTAAAGGAGAGTCCATCTGAGCTGAGATATCTGACCCAGACTGACGACATTT 1140
 DB 1081 AATCTAAAGGAGAGTCCATCTGAGCTGAGATATCTGACCCAGACTGACGACATTT 1140
 QY 1141 GAAGATTTGAGCGCGGAATTTATATGATTAAGTAAACAAATTTCAATCTGACAGT 1200
 DB 1141 GAAGATTTGAGCGCGGAATTTATATGATTAAGTAAACAAATTTCAATCTGACAGT 1200
 QY 1201 AAGCAGTTTAAATAATCTAACAATTTACTTCTTTGTGAGTTATGACAGCAGATGTAACATGT 1260
 DB 1201 AAGCAGTTTAAATAATCTAACAATTTACTTCTTTGTGAGTTATGACAGCAGATGTAACATGT 1260
 QY 1261 GATTAAGACATGTAAGGCTTTGAGATTTGCAATTTATGAAATCTGTAATTAATTTCTAT 1320
 DB 1261 GATTAAGACATGTAAGGCTTTGAGATTTGCAATTTATGAAATCTGTAATTAATTTCTAT 1320

QY 1321 GCAGATTGCCTCAACAGCTTTATATATTAAGCACAATTTACTAG 1362
 DB 1321 GCAGATTGCCTCAACAGCTTTATATATTAAGCACAATTTACTAG 1362
 RESULT 2
 BC018999
 LOCUS
 DEFINITION
 Homo sapiens sphingomyelin phosphodiesterase, acid-like 3A, mRNA
 (CDNA clone MGC:20681 IMAGE:3138813), complete cds.
 ACCESSION
 BC018999
 VERSION
 BC018999.2 GI:33874666
 SOURCE
 MGC.
 Homo sapiens (human)
 ORGANISM
 Homo sapiens
 Bkaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE
 1 (bases 1 to 1759)
 Strausberg, R.L., Fellgould, E.A., Grouse, L.H., Derge, J.G.,
 Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
 Altschul, S.F., Zeeberg, B., Burow, K.H., Schaefer, C.F., Bhat, N.K.,
 Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, P.,
 Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
 Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
 Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,
 Carninci, P., Prange, C., Raha, S.S., Loguercio, N.A., Peters, G.J.,
 Abramson, R.D., Mullany, S.J., Bosak, S.A., McKean, P.J.,
 McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
 Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
 Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
 Fahey, J., Helton, E., Kettelman, M., Madan, A.C., Rodighiero, S.,
 Sanchez, A., Whitting, M., Madan, A., Young, A.C., Shevchenko, Y.,
 Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
 Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
 Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smallus, D.E.,
 Schermer, A., Schein, J.E., Jones, S.J., and Marra, M.A.,
 Generation and initial analysis of more than 15,000 full-length
 human and mouse cDNA sequences
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
 12477932
 2 (bases 1 to 1759)
 Strausberg, R.
 Direct Submision
 Submitted (07-DEC-2001) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2550,
 USA
 NIH-MGC Project URL: <http://mgc.nci.nih.gov>
 On Aug 19, 2003 this sequence version replaced gi:17512052.
 Contact: MGC help desk
 Email: cgabs-remail.nih.gov
 Tissue Procurement: ATCC
 CDNA Library Preparation: Rubin Laboratory
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
 DNA Sequencing by: National Institutes of Health Intramural
 Sequencing Center (NISC),
 Gaithersburg, Maryland;
 Web site: <http://www.nisc.nih.gov/>
 Contact: nisc_mgc@nri.nih.gov
 Akhter, N., Ayele, R., Beckstrom-Sternberg, S.M., Benjamin, B.,
 Blakesley, R.W., Bouffard, G.G., Bren, K., Brinkley, C., Brooks, S.,
 Dietrich, N.L., Granite, S., Guan, X., Gupta, J., Haghighi, P.,
 Hansen, N., Ho, S.-L., Karlins, E., Kong, P., Latic, P., Legaspi, R.,
 Maduro, O.L., Masello, C., Maskeri, B., Mastrian, S.D., McClokey, J.C.,
 McDowell, J., Pearson, R., Stantirip, S., Thomas, P.J., Touchman, J.W.,
 Tsurgoun, C., Vogt, J.L., Walker, M.A., Wetherby, K.D., Wiggins, L.,
 Young, A., Zhang, L.-H. and Green, E.D.
 Clone distribution: MGC clone distribution information can be found
 through the I.M.A.G.E. Consortium/LNL at: <http://image.lnl.gov>
 Series: IRAL Plate: 30 Row: a Column: 7
 This clone was selected for full length sequencing because it
 passed the following selection criteria: matched mRNA gi: 24307910.

QY	36	TCACAGACATGTATTAATAGTGTACATATATGACAAACCAATCAAGCTCTTT	420
Db	429	TCACAGACATGTATTAATAGTGTACATATATGACAAACCAATCAAGCTCTTT	488
QY	421	CCAAATCTCCAGGTTTTCCCTGCGTGGGTATCATGCTATTTGGCCAGAGATCTG	480
QY	489	CCAAATCTCCAGGTTTTCCCTGCGTGGGTATCATGCTATTTGGCCAGAGATCTG	548
QY	481	TCTGATGACACAGTAAAGGTATGACATCAGTAGAAACCTCTG5AAACATGGCTAGAT	540
Db	549	CTGTAGTCCACCAAGTAAAGGTATGACATCAGTAGAAACCTCTG5AAACATGGCTAGAT	608
QY	541	GAAGAGCTATTAGTACTTTAAGGAAGGTGTTTTATTCAACGAAAGTTACACTAT	600
Db	609	GAAAGAGCTATTAGTACTTTAAGGAAGGTGTTTTATTCAACGAAAGTTACACTAT	668
QY	601	CCAAACCTTAGAGATCATCAGTCTAAACCAAACTGTACTAGGCCCAATATATATGACA	660
Db	669	CCAAACCTTAGAGATCATCAGTCTAAACCAAACTGTACTAGGCCCAATATATATGACA	728
QY	661	CTGAACAAAGACTGACCCAGCCACCAAGTTGATGCTAGAAAGTACATTGACACTCT	720
Db	729	CTGAACAAAGACTGACCCAGCCACCAAGTTGATGCTAGAAAGTACACTTGAACAACTCT	788
QY	721	CAGAGAAATAGAGAGAGAGTGTATTCATATGACACATGTTCCAGTGGGGTATCTGCATCT	780
Db	789	CAGAGAAATAGAGAGAGTGTATTCATATGACACATGTTCCAGTGGGGTATCTGCANCT	848
QY	781	TCACAGAACATCACAGCAATGAGAGATATCTATTAATGAAATTGATATTTTTCAA	840
Db	849	TCACAGAACATCACAGCAATGAGAGATATCTATTAATGAAATTGATATTTTTCAA	908
QY	841	AAATACAGTATGTCATTCAGAGACCAATTTATGACACACTCACAGAGACAGATTATG	900
Db	909	AAATACAGTATGTCATTCAGAGACCAATTTATGACACACTCACAGAGACAGATTATG	968
QY	901	GTTCTTTTCAGATPAAAAAAGAAAGTCCAGTAATAATCTTTGTTTGCGCTCTGCTGTACA	960
Db	969	GTTCTTTTCAGATPAAAAAAGAAAGTCCAGTAATAATCTTTGTTTGCGCTCTGCTGTACA	1028
QY	961	CCAGTGAAGAGTGTTTTGA5AAAAACAGACCAACATCTGGTATCAGCTGTTCAATAT	1020
Db	1029	CCAGTGAAGAGTGTTTTGA5AAAAACAGACCAACATCTGGTATCAGCTGTTCAATAT	1088
QY	1021	GATCTCTGATATTAATAATTAATGGATATGTCGACATTACTTGATCTGACAGAGCG	1080
Db	1089	GATCTCTCTGATATTAATAATTAATGGATATGTCGACATTACTTGATCTGACAGAGCG	1148
QY	1081	AATCTAAAGGAGAGTCCATCTGGAGAGTGGAGTATTCGAGCCACAGCTACAGACAT	1140
Db	1149	AATCTAAAGGAGAGTCCATCTGGAGAGTGGAGTATTCGAGCCACAGCTACAGACAT	1208
QY	1141	GAAATTTTGACGCCGGAAGTTTATATGATGATTAAGCTAAACAATTTACATCTTGACAGT	1200
Db	1209	GAAATTTTGACGCCGGAAGTTTATATGATGATTAAGCTAAACAATTTACATCTTGACAGT	1268
QY	1201	AAGCAGTTTATTAATAATCTACAAATTAATCTTTTGAGATTAATGACAGAGTGAACATGT	1260
Db	1269	AAGCAGTTTATTAATAATCTACAAATTAATCTTTTGAGATTAATGACAGAGTGAACATGT	1328
QY	1261	GATTAAGACATGTAAAGGCTTTTCAGATTTGTGCATTAATGAATCTTGATATATTTCTAT	1320
Db	1329	GATTAAGACATGTAAAGGCTTTTCAGATTTGTGCATTAATGAATCTTGATATATTTCTAT	1388
QY	1321	GCAGATGGCTCAAAACAGCTTTATTAATTAAGACAAATTTCTAG	1362
Db	1389	GCAGATGGCTCAAAACAGCTTTATTAATTAAGACAAATTTCTAG	1430

RESULT 6			
AX281695			
LOCUS			
AX281695	1746 bp	DNA	linear
		PAT	02-NOV-2001

DEFINITION	Sequence 104 from Patent WO0177389.
ACCESSION	AX281695
VERSION	AX281695.1
KEYWORDS	GI:16608946
SOURCE	
ORGANISM	Homo sapiens (human)
	Homo sapiens
	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE	
AUTHORS	1 Shiffman,D., Somogyi,R., Lawn,R., Seilhammer,J.J., Porter,G.J.,
TITLE	Mikita,T. and Tal,J.
JOURNAL	Genes expressed in foam cell differentiation
	Patent: WO 0177389-A 104 18-OCT-2001;
	Incyte Genomics, Inc. (US)
FEATURES	
SOURCE	Location/Qualifiers
	1..1746
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
	/note="Incyte ID No: 233778.9"
ORIGIN	
Query Match	99.1%; Score 1349.4; DB 6; Length 1746;
Best Local Similarity	99.9%; Pred. No. 0;
Matches 1361; Conservative	0; Mismatches 1; Indels 1; Gaps 1.

QY	1	ATGGCGCTGGTGGCGCGAC-TGGTCTGCTGCTTGCTGACTGCTTGGA	CTGCGCTGGCACTGCGCTGCTGG	59
Db	69	ATGGCGCTGGTGGCGCGACCTTGCTGCTGCTGCTGCTGCTGCTG	CACTGCGCTGGCACTGCGCTGCTGG	128
QY	60	CTTCGGGCTGCGCGTGGCGCGCGGAGGCGGAGGAATCTCTGCGG	GATGAGCACTT	119
Db	129	CTTCGGGCTGCGCGTGGCGCGCGGAGGCGGAGGAATCTCTCTCG	GGAATGAGCACTT	188
QY	120	TTGGCATGTGACTGACTTACACTTAGACCCCTACTTACACATCA	CAGATGACCAACAAA	179
Db	189	TTGGCATGTGACTGACTTACACTTAGACCCCTACTTACACATCA	CAGATGACCAACAAA	248
QY	180	AGTGTGTCTTCACTCTAAAGGTGCAAAATGCTCTCAACCTTG	CGCTTTTGGAGATGTTCT	239
Db	249	AGTGTGTCTTCACTCTAAAGGTGCAAAATGCTCTCAACCTTG	CGCTTTTGGAGATGTTCT	308
QY	240	GTTGATTTCTCCATATCACTTATTTTGTGCGACTTTGATTTT	TTTAAATTCGAGCA	299
Db	309	GTTGATTTCTCCATATCACTTATTTTGTGCGACTTTGATTTT	TTTAAATTCGAGCA	368
QY	300	AGAAGCATCTTTCATGATATGACAGGGGATAGCCACTCATG	TTCCTGTACCTGAAT	359
Db	369	AGAAGCATCTTTCATGATATGACAGGGGATAGCCACTCATG	TTCCTGTACCTGAAT	428
QY	360	CTCAACAGACCTGTTATTAATGTGATCACTAATATGACAA	CCACCATCCAGATCTCTT	419
Db	429	CTCAACAGACCTGTTATTAATGTGATCACTAATATGACAA	CCACCATCCAGATCTCTT	488
QY	420	TTCCAAATCTCAGGTTTTCCCTGGCGTGGATATCAGATCAT	ATGCGCACAGGATCACT	479
Db	489	TTCCAAATCTCAGGTTTTCCCTGGCGTGGATATCAGATCAT	ATGCGCACAGGATCACT	548
QY	480	GTCGTGTAGTCAACAGTAAAGTACAAATGACATGACAA	ACTCTTGGAACCATGGCTAGA	539
Db	549	GTCGTGTAGTCAACAGTAAAGTACAAATGACATGACAA	ACTCTTGGAACCATGGCTAGA	608
QY	540	TGAAGAAGCTATTAGTACTTTAAGAAAAGTGTTTTTATTC	ACAGAAAATTACAATPA	599
Db	609	TGAAGAAGCTATTAGTACTTTAAGAAAAGTGTTTTTATTC	ACAGAAAATTACAATPA	668
QY	600	TTCAAACCTTATGATCATCAGTCTTAAACAACTTGTATCTA	CGGCCCAATATATATGAC	659
Db	669	TTCAAACCTTATGATCATCAGTCTTAAACAACTTGTATCTA	CGGCCCAATATATATGAC	728
QY	660	ACTGAACAAGCTAGACCCAGCCAAACCACTTTGAATGGT	ATAGAAAGTACATTTGAACAATCTC	719
Db	729	ACTGAACAAGCTAGACCCAGCCAAACCACTTTGAATGGT	ATAGAAAGTACATTTGAACAATCTC	788

QY 720 TCAGCAGAAATAGAGAGAGGATATATCATAGCAGATGTCAGTGGGGATCTGCATC 779
DB 789 TCAGCAGAAATAGAGAGAGGATATATCATAGCAGATGTCAGTGGGGATCTGCATC 848
QY 780 TTCACGAAATCATCAGCAATAGAGAAATCTATATGAGAAATGTATAGATATTTTCA 839
DB 849 TTCACGAAATCATCAGCAATAGAGAAATCTATATGAGAAATGTATAGATATTTTCA 908
QY 840 AAAATACAGTATGTCATTCAGAGCAATTTTATGACACACTCAGAGACAGCATAT 899
DB 909 AAAATACAGTATGTCATTCAGAGCAATTTTATGACACACTCAGAGACAGCATAT 968
QY 900 GGTTCCTTTCAGATAAAAAGAGATCCAGTAAATCTTTGTTGGCTCCTGCTGTAC 959
DB 969 GGTTCCTTTCAGATAAAAAGAGATCCAGTAAATCTTTGTTGGCTCCTGCTGTAC 1028
QY 960 ACCAGTGAAGATGTTTATAGAAAAACAGACCAATCTGATATCAGACTGTTTCAGTA 1019
DB 1029 ACCAGTGAAGATGTTTATAGAAAAACAGACCAATCTGATATCAGACTGTTTCAGTA 1088
QY 1020 TGAATCTCGTATTAATTAATTTGATATGTTGCAATTTACTGATCTGACAGAGGC 1079
DB 1089 TGAATCTCGTATTAATTAATTTGATATGTTGCAATTTACTGATCTGACAGAGGC 1148
QY 1080 GAATCTTAAGAGAGATCCATCTGAGAGCTGAGATATCTGATCCAGACCTACAGCAT 1139
DB 1149 GAATCTTAAGAGAGATCCATCTGAGAGCTGAGATATCTGATCCAGACCTACAGCAT 1208
QY 1140 TGAAGATTTGACGCGGAAAGTTATATGATTAAGTAAACAATTTCAATCTAGACAG 1199
DB 1209 TGAAGATTTGACGCGGAAAGTTATATGATTAAGTAAACAATTTCAATCTAGACAG 1268
QY 1200 TAAGCATTTATATAATATCTACATTAATCTTTGTTGATGATTAAGACAGCTGTAATG 1259
DB 1269 TAAGCATTTATATAATATCTACATTAATCTTTGTTGATGATTAAGACAGCTGTAATG 1328
QY 1260 TGAATTAAGACATTAAGAGCTTTGATGATTAAGTAAACAATTTCAATCTAGACAG 1319
DB 1329 TGAATTAAGACATTAAGAGCTTTGATGATTAAGTAAACAATTTCAATCTAGACAG 1388
QY 1320 TGCAGATTTGCTCAAAACAGCTTTATATTAAGCAATTTACTAG 1362
DB 1389 TGCAGATTTGCTCAAAACAGCTTTATATTAAGCAATTTACTAG 1431

RESULT 7
AX780232 2505 bp DNA linear PAT 14-JUL-2003
LOCUS Sequence 2389 from Patent WO03039443.
DEFINITION AX780232
ACCESSION AX780232.1 GI:32697226
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Hafferlach, T., Schoch, C., Kern, W., Kohlmann, A., Schultze, S.,
Dugas, M., Ellis, R., Broers, B. and Mergenthaler, S.
TITLE Novel genetic markers for leukemias
JOURNAL Patent: WO 03039443-A 2389 15-MAY-2003;
Deutsches Krebsforschungszentrum (DE) ;
Ludwig-Maximilians-Universitaet Muenchen
PD Dr. Dr. Schoch, Claudia (DE) ; Kern, Wolfgang (DE)
location/Qualifiers
1. 2505
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 98.5%; Score 1341.4; DB 6; Length 2505;

Best Local Similarity 99.3%; Pred. No. 0;
Matches 1353; Conservative 0; Mismatches 9; Indels 1; Gaps 1;
QY 1 ATGGCCCTGGTGGGCGGCACTCTCTCTGCGC-TGCTGACTGCTCTGCACTGCGGCTCCGG 59
DB 590 ATGGCCCTGGTGGGCGGCACTCTCTCTGCGC-TGCTGACTGCTCTGCACTGCGGCTCCGG 649
QY 60 CTCGGGCTGCGCGGTGGCGCGGCGGCAAGAAATCTCTCTCGGCGATAGAACGTT 119
DB 650 CTCGGGCTGCGCGGTGGCGCGGCGGCAAGAAATCTCTCTCGGCGATAGAACGTT 709
QY 120 TTGCGATGTCAGTACTTACCTTAAGACCTTACTTACACATGACAGATGACACAAA 179
DB 710 TTGCGATGTCAGTACTTACCTTACCTTACTTACACATGACAGATGACACAAA 769
QY 180 AGTGTGCTTCACTTAAGAGTCAATATGCTCCAAATCCCTGGCCCTTTTGGAAATGTTCT 239
DB 770 AGTGTGCTTCACTTAAGAGTCAATATGCTCCAAATCCCTGGCCCTTTTGGAAATGTTCT 829
QY 240 GTGTGATTCCTCATATCACTTATTTTGTGAGCAATTTATTTTAAATTTCTGGACA 289
DB 830 GTGTGATTCCTCATATCACTTATTTTGTGAGCAATTTATTTTAAATTTCTGGACA 889
QY 300 AGAAGCATCTTTCATGATATGACAGAGGATAGCCCACTCATGTTCTGTACTGAACT 359
DB 890 AGAAGCATCTTTCATGATATGACAGAGGATAGCCCACTCATGTTCTGTACTGAACT 949
QY 360 CTCACAGACACTGTTATTAATATGATCACTAATATGACACCAATCCAGAGTCTTT 419
DB 950 CTCACAGACACTGTTATTAATATGATCACTAATATGACACCAATCCAGAGTCTTT 1009
QY 420 TCCAAATCTCAGATTTTCCCTGCGCTGGGATTCATGATTTATTTGGCAAGATCACT 479
DB 1010 TCCAAATCTCAGATTTTCCCTGCGCTGGGATTCATGATTTATTTGGCAAGATCACT 1069
QY 480 GTCTGATGTCAGCAATTAAGTATGATGATGATGATGATGATGATGATGATGATGATG 539
DB 1070 GTCTGATGTCAGCAATTAAGTATGATGATGATGATGATGATGATGATGATGATGATG 1129
QY 540 TGAAGAGCTATTAATGATCTTTTAAGAAAGGTGTTTATTCACAGAAATTTCAACTAA 599
DB 1130 TGAAGAGCTATTAATGATCTTTTAAGAAAGGTGTTTATTCACAGAAATTTCAACTAA 1189
QY 600 TCCAAATCTTAGATCATGATGATGATGATGATGATGATGATGATGATGATGATGATG 659
DB 1190 TCCAAATCTTAGATCATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1249
QY 660 ACTGAACAAGACTGACCCAGCCCAACAGATTTGATGATGATGATGATGATGATGATGATG 719
DB 1250 ACTGAACAAGACTGACCCAGCCCAACAGATTTGATGATGATGATGATGATGATGATGATG 1309
QY 720 TCAGCAGAAATAGAGAGAGGATATATCATAGCAGATGTCAGTGGGGATCTGCATC 779
DB 1310 TCAGCAGAAATAGAGAGAGGATATATCATAGCAGATGTCAGTGGGGATCTGCATC 1369
QY 780 TTCACGAAATCATCAGCAATAGAGAAATCTATATGAGAAATGTATAGATATTTTCA 839
DB 1370 TTCACGAAATCATCAGCAATAGAGAAATCTATATGAGAAATGTATAGATATTTTCA 1429
QY 840 AAAATACAGTATGTCATTCAGAGCAATTTTATGACACACTCAGAGACAGCATAT 899
DB 1430 AAAATACAGTATGTCATTCAGAGCAATTTTATGACACACTCAGAGACAGCATAT 1489
QY 900 GGTTCCTTTCAGATAAAAAGAGATCCAGTAAATCTTTGTTGGCTCCTGCTGTAC 959
DB 1490 GGTTCCTTTCAGATAAAAAGAGATCCAGTAAATCTTTGTTGGCTCCTGCTGTAC 1549
QY 960 ACCAGTGAAGATGTTTATAGAAAAACAGACCAATCTGATATCAGACTGTTTCAGTA 1019
DB 1550 ACCAGTGAAGATGTTTATAGAAAAACAGACCAATCTGATATCAGACTGTTTCAGTA 1609
QY 1020 TGAATCTCGTATTAATTAATTTGATATGTTGCAATTTACTGATCTGACAGAGGC 1079

Db	1610	TGATCCTCGTATTATAAATTATTTGGATATGTTGCAATTAAGTAACTTGAATCTGCAGAGGC	1669
Qy	1080	GAATCTAAGAGSAGACATCTGGAAGCTGAGATATATCCTGACCAGACCTAGACAT	1139
Db	1670	GAATCTAAGSAGAGCTCATCTGGAAGCTGAGATATCTTGACCAGACCTTAGACAT	1729
Qy	1140	TGAAGATTTCAGCCGGAAAGTTTATATGATTAGCTTAAACAATTTTCAATCTTAGACAG	1199
Db	1730	TGAAGATTTCAGCCGGAAAGTTTATATGATTAGCTTAAACAATTTTCAATCTTAGACAG	1789
Qy	1200	TAAACAGTTTATAAATATATCATCATTTACTCTTTGTGAGTATAGACAGCATGTAAACATG	1259
Db	1790	TAAACAGTTTATAAATATATCATCATTTACTCTTTGTGAGTATAGACAGCATGTAAACATG	1849
Qy	1260	TGATTAAGACATGTAAAGCCCTTTCAGATTTCGACATTAATGAATCTTGTATAATATTTCTTA	1319
Db	1850	TGATTAAGACATGTAAAGCCCTTTCAGATTTCGACATTAATGAATCTTGTATAATATTTCTTA	1909
Qy	1320	TGCGAATTCGCTCAACACAGCTTTTATATAACACAAATTACAG	1362
Db	1910	TGCGAATTCGCTCAACACAGCTTTTATATAACACAAATTACAG	1952

LOCUS	COA14095	2049 bp	DNA	linear	PAT 23-JAN-2004
DEFINITION	Sequence 21166 from Patent WO0170979.				
ACCESSION	COA14095				
VERSION	COA14095.1	GI:41321876			
KEYWORDS					
SOURCE					
ORGANISM	Homo sapiens (human)				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1				
AUTHORS	Lee, J. and Hillie, J.				
TITLE	Genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer				
JOURNAL	Patent: WO 0170979-A 21166 27-SEP-2001;				
	Millennium Pharmaceuticals, Inc. (US)				
FEATURES					
SOURCE	Location/Qualifiers				
	1..2049				
	/organism="Homo sapiens"				
	/mol_type="unassigned DNA"				
	/db_xref="taxon:9606"				
ORIGIN					
Query Match	76.0%; Score 1035.4; DB 6; Length 2049;				
Best Local Similarity	99.9%; Pred. No. 1.5e-246;				
Matches 1036; Conservative	0; Mismatches	1; Indels	0; Gaps	0;	
QY	326	GGGATAGCCCA	CCCTCATGTTCCCTGATCTGTAAC	CTCTCAACAGACAGCTTTAATG	TGA 385
Db	210	GGGATAGCCCA	CCCTCATGTTCCCTGATCTGTAAC	CTCTCAACAGACAGCTTTAATG	TGA 269
QY	386	TCACTAATATG	ACAACCAACATCCAGAGTCCTTCCCAATCTCAGGTTTCCCTG	CGC 445	
Db	270	TCACTAATATG	ACAACCAACATCCAGAGTCCTTCCCAATCTCAGGTTTCCCTG	CGC 329	
QY	446	TGGGTAAATCA	TGACTATTGGCCACAGATCAACTGTCTGTAGTCA	CCAGTAAAGTTACA 505	
Db	330	TGGGTAAATCA	TGACTATTGGCCACAGATCAACTGTCTGTAGTCA	CCAGTAAAGTTACA 389	
QY	506	ATGCAAGTAGCA	AAACCTCTGGAACCAATGGCTAGATGAAAGAGTATAGTACTTTA	AGGA 565	
Db	390	ATGCAAGTAGCA	AAACCTCTGGAACCAATGGCTAGATGAAAGAGTATAGTACTTTA	AGGA 449	
QY	566	AAGGTGTTTTT	ATTATTCAGAAAGTTACAACTAATCCAACTTAGATCATCAGTCTAA 625		
Db	450	AAGGTGTTTTT	ATTATTCAGAAAGTTACAACTAATCCAACTTAGATCATCAGTCTAA 509		
QY	626	ACACAACTTG	TACTAGGCGCCAAATATATGACATGAAACAAAGCTGACCCAGCACC 685		

Db	510	ACGCAAACTTGATCTAGCGGCCAAATATTAATGACATGGAACAAAGACTGACCAGCAAC	569
Qy	686	AGTTGGAATGGCTAAGAAAGTACATTTGAAACACTCTGACGAGAAATAGGAGAGGTAT	745
Db	570	AGTTGATATGGCTAAGAAAGTACATTTGAAACACTCTGACGAGAAATAGGAGAGGTAT	629
Qy	746	TCATAGCACATGTTCCAGTGGGGTATCTGCATCTTTCACAGACATCAACGAAATGAG	805
Db	630	TCATAGCACATGTTCCAGTGGGGTATCTGCATCTTTCACAGACATCAACGAAATGAG	689
Qy	806	AATTCATTAATGAGAAATTTGATAGATATTTTTCAAAAATACAGATGCTATTCAGAC	865
Db	690	AATTCATTAATGAGAAATTTGATAGATATTTTTCAAAAATACAGATGCTATTCAGAC	749
Qy	866	AATTTTATGACACACTCAGAGAGACAGACATTAATGTTCTTTCAGATAAAAAGAAAGTC	925
Db	750	AATTTTATGACACACTCAGAGAGACAGACATTAATGTTCTTTCAGATAAAAAGAAAGTC	809
Qy	926	CAGTAAATCTCTTGTGTGTGGCTCTGCTGTTCACACAGTGAAGAGTTTTAAAGAAAC	985
Db	810	CAGTAAATCTCTTGTGTGTGGCTCTGCTGTTCACACAGTGAAGAGTTTTAAAGAAAC	869
Qy	986	AGACCAACAAATCCCTGGATCAGACTGTTTCAGTATGATCCCTCGATTAATAATTAATGG	1045
Db	870	AGACCAACAAATCCCTGGATCAGACTGTTTCAGTATGATCCCTCGATTAATAATTAATGG	929
Qy	1046	ATATGTTCAGATTAATCTTGAATCTGAACAAGCGAAATCTTAAAGGAGAGTCCATCTGGA	1105
Db	930	ATATGTTCAGATTAATCTTGAATCTGAACAAGCGAAATCTTAAAGGAGAGTCCATCTGGA	989
Qy	1106	AGCTGAGTATATCCCTACCCAGACCTACAGCACTTGAAGATTTTCAGCCGGAAGTTAT	1165
Db	990	AGCTGAGTATATCCCTACCCAGACCTACAGCACTTGAAGATTTTCAGCCGGAAGTTAT	1045
Qy	1166	ATGGAATTAAGTAAACAATTTACATCTCTAGACAGTAAAGCACTTATTAATAATCTACAAT	1225
Db	1050	ATGGAATTAAGTAAACAATTTACATCTCTAGACAGTAAAGCACTTATTAATAATCTACAAT	1109
Qy	1226	ACTTCTTTTGAGTATGACAGACAGTGTACATGATGTAAGAATGTAAGGCTTTTCAGA	1289
Db	1110	ACTTCTTTTGAGTATGACAGACAGTGTACATGATGTAAGAATGTAAGGCTTTTCAGA	1165
Qy	1286	TTTGTGCATTAATGAATCTTGATATATTTTCTATGACAGATTTGCCTCAACAGCTTTATA	1345
Db	1170	TTTGTGCATTAATGAATCTTGATATATTTTCTATGACAGATTTGCCTCAACAGCTTTATA	1229
Qy	1346	TAAAGCACTTAATCTAG 1362	
Db	1230	TAAAGCACTTAATCTAG 1246	

RESULT	9
AX305693	
LOCUS	AX305693
DEFINITION	AX305693 1758 bp DNA linear PAT 11-DEC-2001
ACCESSION	Sequence 444 from Patent WO0188188.
VERSION	AX305693
KEYWORDS	AX305693.1 GI:17645124
SOURCE	.
ORGANISM	Mus musculus (house mouse)
	Mus musculus
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1
AUTHORS	Ishikawa,K., Asai,S., Takahashi,Y., Nagata,T. and Ishii,Y.
TITLE	Method for examining ischemic conditions
JOURNAL	Patent: WO 0188188-A 444 22-NOV-2001;
	School Juridical Person Nihon University (JP)
FEATURES	Location/Qualifiers
source	1..1758
	/organism="Mus musculus"
	/mol_type="unassigned DNA"
	/db_xref="taxon:10090"
ORIGIN	

Wed Apr 6 15:08:45 2005

Search completed: April 5, 2005, 09:16:57
Job time : 5850 secs

us-09-823-119b-3.rge

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: April 5, 2005, 10:08:58 ; Search time 628 Seconds
(without alignments)
4270.132 Million cell updates/sec

Title: US-09-823-119b-1

Perfect score: 2427
Sequence: 1 MALVRLVCLLTMHCRSG.....NLDNISYADCLKQYIKENY 453

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 4390206 segs, 2959870667 residues

Total number of hits satisfying chosen parameters: 8780412

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp
-Q=/cgn2.1/USPRO.spool_p/US09823119/runac_05042005_084015_6991/app_query.fasta_1.647
-DB=N_Geneseq_16Dec04 -QMT=fastap -SUFFIX=ring -MINMATCH=0.1 -LOOPL=0
-LOOPEXT=0 -UNITS=bites -START=1 -END=-1 -MATRIX=blomsum62 -TRANS=human40.cdd
-LIST=45 -DOCALLIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=pco -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US09823119_QCGN_1_1_708 @runac_05042005_084015_6991 -NCPU=6 -ICPU=3
-NO_MMAP -LARGEOBURY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :

N_Geneseq_16Dec04:
1: geneseq1980s:
2: geneseq1990s:
3: geneseq2000s:
4: geneseq2001as:
5: geneseq2001bs:
6: geneseq2002as:
7: geneseq2002bs:
8: geneseq2003as:
9: geneseq2003bs:
10: geneseq2003cs:
11: geneseq2003ds:
12: geneseq2004as:
13: geneseq2004bs:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2427	100.0	1362	4	AAD21343 Human nuc
2	2422	99.8	1763	10	ADH61155 Human hyd
3	2422	99.8	1764	4	AAC60227 Human hyd
4	2422	99.8	1764	9	ADA10929 Human CDN
5	2422	99.8	1764	10	ADB90834 Human CDN

6	2422	99.8	1768	12	ADJ45508	Adj45508 cDNA enco
7	2413	99.4	1783	6	AA562765	AA562765 cDNA sequ
8	2409	99.3	1746	6	AA594849	AA594849 Human DNA
9	2355	97.0	2505	10	ADP81833	ADP81833 Leukemia
10	2223	91.6	1873	4	AA161110	AA161110 Human pol
11	2223	91.6	1874	4	AA159324	AA159324 Human pol
12	1962.5	80.9	2049	5	ADL62954	ADL62954 Human ova
13	1953.5	80.5	1758	6	AB194882	AB194882 Mouse isc
14	1903.5	78.4	1095	4	AAD21344	AAD21344 Human nuc
15	1209	49.8	728	3	AAA02374	AAA02374 Human col
16	1162	47.9	733	3	AAA02333	AAA02333 Human col
17	1101	45.4	939	5	AAH20423	AAH20423 Human sph
18	1004	41.4	559	6	ABN60406	ABN60406 Human can
19	986.5	40.6	778	3	AAA02346	AAA02346 Human col
20	956	39.4	773	3	AAA02332	AAA02332 Human col
21	932	38.4	540	6	ABN60975	ABN60975 Human can
22	930	38.3	863	6	ABL62490	ABL62490 Colon ade
23	930	38.3	863	6	ABL61985	ABL61985 Colon ade
24	930	38.3	863	6	ABK84743	ABK84743 Human CDN
25	930	38.3	863	8	ACA89936	ACA89936 Gene diff
26	930	38.3	863	10	ADH28998	ADH28998 Human chr
27	930	38.3	863	13	ADP24656	ADP24656 PRO polyP
28	921	37.9	1489	4	AAH99916	AAH99916 Nucleotid
29	921	37.9	1814	4	AA159259	AA159259 Human pol
30	921	37.9	1816	4	AA161045	AA161045 Human pol
31	917	37.8	1610	6	ABL68027	ABL68027 Ovary can
32	917	37.8	1610	6	ABL64782	ABL64782 Lung can
33	878	36.2	610	10	ADB90860	ADB90860 Human hyd
34	878	36.2	610	10	ADH61181	ADH61181 Human hyd
35	598.5	24.7	1902	4	ADB90862	ADB90862 Human hyd
36	543	22.4	317	10	ADH61183	ADH61183 Human hyd
37	543	22.4	317	10	ADH61183	ADH61183 Human hyd
38	519	21.4	300	3	AAA00750	AAA00750 Human col
39	514.5	21.2	3264	4	ABL6061	ABL6061 Drosophill
40	486.5	20.0	1879	6	ABL59530	ABL59530 Human sph
41	486.5	20.0	2344	2	AAQ33394	AAQ33394 R496L ASM
42	486.5	20.0	2344	2	AAQ35066	AAQ35066 cDNA enco
43	486.5	20.0	2344	9	ACD28698	ACD28698 cDNA enco
44	486.5	20.0	2347	2	AAQ33390	AAQ33390 ASM cDNA
45	486.5	20.0	2347	2	AAQ35067	AAQ35067 cDNA enco

ALIGNMENTS

RESULT 1	
AAD21343	
ID	AAD21343 standard; cDNA; 1362 BP.
XX	
AC	AAD21343;
XX	
DT	28-JAN-2002 (first entry)
XX	
DE	Human nuclear factor kappaB-inducing factor (NFIF)-14b cDNA.
XX	
KW	Human; NFkappaB; nuclear factor kappaB inducing factor; NFIF-14b;
KW	NRIF-7a; immune response; inflammatory response; atherosclerosis;
KW	rheumatoid arthritis; NSAID-induced gastropathy; sepsis;
KW	neurodegenerative disease; autoimmune disease; antitense therapy;
KW	renal disease; restenosis; brain injury; viral disease; apoptosis;
KW	Alzheimer's disease; pleiotropic cytokine; gene therapy; aetnaia;
KW	Crohn's disease; ss.
XX	
OS	Homo sapiens.
XX	
PH	
FT	Key
FT	CDS
FT	Location/Qualifiers
FT	1..1362
FT	/*tag= a
FT	/product= "Human NFIF-14b protein"
XX	
PN	W0200174900-A2.
XX	
PD	11-OCT-2001.
XX	

PF 02-APR-2001; 2001WO-US010719.
XX 31-MAR-2000; 2000US-0193905P.
PR 26-JUL-2000; 2000GB-00018307.
XX
XX (AVET) AVENTIS PHARM PROD INC.
XX
PI Kaplow J, Haws T, Rosier M, Deneffe P;
XX WPI; 2001-662967/76.
DR P-PSDB; AAE13018.
XX
PT Novel isolated nuclear factor kappaB-inducing factor polypeptides (NFIF-
7a, NFIF-14b), useful for increasing NFkappaB induction in patient, and
PT for manufacturing medicaments for treating or preventing atherosclerosis.
XX
PS Claim 1; Fig 3; 87pp; English.
XX
CC The invention relates to nuclear factor kappaB (NFkappaB) inducing factor
CC NFIF-14b, NFIF-7a (splice variant of NFIF14b) polypeptides and
CC polynucleotides. NFIF-14b and NFIF-7a sequences are useful for inducing
CC NFkappaB in vivo for increasing the activity of NFkappaB-regulated
CC pathways including immune responses. Compositions comprising NFIF
CC sequences are useful for treating or preventing NFkappaB-regulated
CC inflammatory response such as rheumatoid arthritis, atherosclerosis,
CC autoimmune diseases, viral diseases, NSAID-induced gastropathy,
CC neurodegenerative diseases, sepsis, apoptosis, Crohn's disease,
CC renal disease, restenosis, brain injury/inflammation, Alzheimer's
CC disease, asthma and improperly regulated expression of pleiotropic
CC cytokines. They are also useful for inhibiting or lowering the expression
CC of NFIF genes or polypeptides, respectively and thus for inhibiting
CC induction of NFkappaB and consequently inhibiting or preventing NFkappaB-
CC regulated immune responses that result in atherosclerosis and other
CC diseases. Polynucleotides of the invention are useful in gene therapy and
CC antisense therapy. The present sequence is human NFIF-14b cDNA
XX
SQ Sequence 1362 BP; 419 A; 291 C; 274 G; 378 T; 0 U; 0 Other;
XX
Alignment Scores:
Pred. No.: 2.66e-224 Length: 1362
Score: 2427.00 Matches: 453
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 4 Gaps: 0
US-09-823-119B-1 (1-453) x AAD21343 (1-1362)
QY 1 MetAlaLeuValArgAlaLeuValCysAspLeuThrAlaTrpHisCysArgSerGly 20
Db 1 ATGGCGCTGGTGGCGGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCGC 60
QY 21 LeuGlyLeuProValAlaProAlaGlyGlyArgAsnProProProAlaIleGlyGlnPhe 40
Db 61 CTCGGGCTGCCCGGGCGCCGCGAGGCGGAGAACTCTCCGCGCATAGGACAGATT 120
QY 41 TrpHisValThrAspLeuHisLeuAspProThrTrpHisIleThrAspAsnHisThrIlys 60
Db 121 TGGCAATGAGCTGACTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTACCTTAC 180
QY 61 ValCysAlaSerSerGlyGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValLeu 80
Db 181 GTGTGTGCTTATCATTAAGAGTGAAGTCCCTCCCAACCTGGCCCTTTGGAGATGTTCTG 240
QY 81 CysAspSerProGlyGlnLeuIleuSerAlaPheAspPheIleuAsnSerGlyGln 100
Db 241 TGTGATTTCTCATATCAACTATTTTTCACACATTTGATTTTAAATAAATCTCGACAA 300
QY 101 GluAlaSerPheMetIleTrpThrGlyAspSerProProHisValProValProGlnLeu 120
Db 301 GAAGCATCTTTCATGATATGAGACAGGGAGTACCCACCTCACTGTTCCGTACCTGAATCTC 360
QY 121 SerThrAspThrValIleAsnValIleThrAsnMetThrThrThrIleGlnSerLeuPhe 140

Db 361 TCACACAGACACTGTTAATAAATGGATCATTAATATGACCAACCACTCCAGAGCTCTTT 420
QY 141 ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTrpTrpProGlnAspGlnLeu 160
Db 421 CCAATCTCCAGAGTTTCCCTGGCGCTGGTAATCATCATTAATGGCCACAGGATCAACTG 480
QY 161 SerValValThrSerLeuValIleAsnAlaValAlaAsnLeuTrpLeuAspProTrpLeuAsp 180
Db 481 TCTGTAGTACCCAGTTAAGTATGATCATATGATGACATGACCAACCTCTGGAAACCATGGCTGAT 540
QY 181 GluGlnAlaIleSerThrLeuArgGlyGlyPheTrpSerGlnValIleThrAsn 200
Db 541 GAAGACACTATTGATCTTTAAGGAAGTGGTTTATTACAGAAAGTTACAACTAAT 600
QY 201 ProAsnLeuArgIleSerLeuAsnThrAsnLeuTrpGlyProAsnIleMetThr 220
Db 601 CCAAACTTAGATGATCATCACTTAACCAAACTGTACTACGCGCCCAATATTAATGACA 660
QY 221 LeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGlnSerThrLeuAsnAsnSer 240
Db 661 CTGAACAGACTGACCCAGCCACCACTTGAATGCTTGAAGTACATTGACCACTCT 720
QY 241 GlnGlnAsnLysGlnLysValIleIleIleAlaHisValProValGlyTrpLeuProSer 260
Db 721 CAGCAGATATAGAGGAAGGTATATCATATGACATGTTCCAGTGGGGTATCTGCCATCT 780
QY 261 SerGlnAsnIleThrAlaMetArgGluTrpTrpAsnGlyLeuLeuIleAspIlePheGln 280
Db 781 TCACAGAACATCACAGAAAGAGAGTACTAATATGAAGATGATATTTTTCAA 840
QY 281 LysTrpSerAspValIleAlaGlyGlnPheTrpGlyHisThrHisArgAspSerIleMet 300
Db 841 AAATACGTATGTCATTTGACGACAAATTTTATGACACACTACAGACAGACATTAATG 900
QY 301 ValLeuSerAspLysGlySerProValAsnSerLeuPheValAlaProAlaValThr 320
Db 901 GTCTTTCAATATAAAGAAAGAGCCAGTAATCTTTGTTGGCTCGCTGTTACA 960
QY 321 ProValLysSerValLeuGlyLysGlnThrAsnAsnProGlyIleArgLeuPheGlnTrp 340
Db 1081 AATCTAAAGGAGAGTCCATCTGGAGCTGGAATATCTTGACCCAGACCTTACGACATT 1140
QY 381 GluAspLeuGlnProGlnSerLeuTrpGlyLeuAlaLysGlnPheThrIleLeuAspSer 400
Db 1141 GAAGATTTTGAAGCCGGAAGTTTATATGATTAAGCTTAACAAATTTTAACTTACAGAGT 1200
QY 401 LysGlnPheIleLysTrpTrpAsnTrpPhePheValSerTrpAspSerSerValThrCys 420
Db 1201 AAGCAGTTTATTAATATCTACATTAATCTTTGTGAGTTTATGACGACATGTAACATGT 1260
QY 421 AspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTrp 440
Db 1261 GATTAAGACATGTAAGGCTTTCAGATTGTGCAATTTGAATCTTGTATATATTCTAT 1320
QY 441 AlaAspCysLeuLysGlnLeuTrpIleLysHisAsnTrp 453
Db 1321 GCAGATTGCTCAAAACAGCTTTATATTAAGCACAAATTAC 1359
RESULT 2
ADH61155 standard; cDNA; 1763 BP.
ID ADH61155
XX ADH61155;
AC
XX

DT		25-MAR-2004	(first entry)
XX			
DE		Human hydrolase-like molecule (HHLM) 5 cDNA #1.	
KX		Human; hydrolase-like molecule; HLM; cancer; arteriosclerosis;	
KW		cycostatic therapy; gene; ss.	
XX			
OS	Homo sapiens.		
XX			
FH	Key	Location/Qualifiers	
FT	CDS	/tag= a 68..1429	
FT		/product= "human hydrolase-like molecule (HHLM) protein"	
NN	US2003148363-A1.		
XX			
PD	07-AUG-2003.		
XX			
PF	05-FEB-2003; 2003US-00359499.		
XX			
PR	06-FEB-1998; 98US-00013881. 07-JUL-2000; 2000US-00612473.		
XX			
PA	(INCYTE GENOMICS INC.)		
XX			
PI	Bandman O, Lal P, Hillman JL, Corley NC, Guegler KJ, Shah P; WP1; 2003-897560/82.		
DR	P-PDB; ADH61147.		
XX			
PT	New human hydrolase-like molecules (HML), useful for preparing a composition for diagnosing, treating or preventing a disease or condition associated with expression of HML e.g. Cancer or arteriosclerosis.		
XX			
XX	Claim 5; SEQ ID NO 13; 60pp; English.		
CC	The invention relates to human hydrolase-like molecules (HML) and their corresponding nucleic acid sequences. The sequences of the invention are useful for preparing a composition for diagnosing or treating a disease or condition associated with decreased expression or over expression of HML e.g., cancer or arteriosclerosis. The present sequence is human hydrolase-like molecule (HML) cDNA.		
SQ	Sequence 1763 BP; 537 A; 356 C; 343 G; 527 T; 0 U; 0 Other;		
Alignment Scores:			
Pred. No.:	1,17e+223	Length:	1763
Score:	2422.00	Matches:	452
Percent Similarity:	99.78%	Conservative:	0
Best Local Similarity:	99.78%	Mismatches:	1
Query Match:	99.79%	Indels:	0
Gaps:	10	Gaps:	0
US-09-823-119B-1 (1-453) x ADH61155 (1-1763)			
DY	1 MetalaleValAlArgAalAleuValCysCySleuleuthrAlatrPhisCysargsergly 20		
Db	68 ATGGGCGCTGTGCAGCACTTCGTCTGCTACACTGCCATGCGCATGCGTCCGCC 127		
OY	21 LeuglyLeuProvalAlarProlagilyglYAgsAsnProFroRosalileglyInphe 40		
Db	128 CTCGGGCTGCCCCGTGGCGCCGCGAGCGGAGGAATCTCTCCGCGGATAGCACAGTTT 187		
OY	41 TRPHlavalThraSpLenthrlseuArpPrOTHrhIstllethrAprasAPHlstThrlys 60		
Db	188 TGcCaRGtAcGaActTAACAATTAgACCCTACTTAACTAACATAAGTGCCAACAACAAA 247		
OY	61 ValCySaLasSerLySGLYlaAnaalaaserAsnProGIyProphegiyaSPvallau 80		
Db	248 GGtGTGTGCTTANTCTRAAGSTGAATGCTCCAACCTGGCCCTTTGGAGAATGTTCTG 307		
OY	81 CyaaApSerProTyGLinleulleuseralaphaspHeilleysaanSenrglyln 1000		

Db	308	GTGATTCCTCCATATCAACTATTATTTGTGCAGCAATTTGATTTTATTAAAAATTCGCACAA	367
OY	101	GIUALaserPheMetC1ETPrThGlyAspSerProPheSValProValProGluLeu	120
Db	368	GAACCACTCTTTCAGATATGACAGGGGGAATAGCCACCTCAATGTTCTGTACCTGAAC	427
OY	121	SerThrAspThrValI1IeAsnValI1eThrAsnMetThrThrTrilEgNSetLeuPhe	140
Db	428	TCAACAGACACTGTTTATTAATATGATGATCACTATATATGACACCACCATTCAGAGTCTCTT	487
OY	141	ProAsnLeuGlnValI1PheProAlaLeuGlyAsnHisAspTyrTrpProGlnAspGlnLeu	160
Db	488	CCAATATCTCCAGGTTTTTCCCGCGCTGGGTATCATGATCATTTGGCCACAGATCAACTG	547
OY	161	SerValValThrSerIysValTyrAsnAlaValAlaAsnLeuTrpIleProTrpLeuAsp	180
Db	548	CCTGTAGTCAACCAATTAAGGTGTACAAAGCAGTACCAACCTCTGAAACCATGCTGTAT	607
OY	181	GlnGlnAlaIleSerThrLeuAspGlyGlyGlyPheTyrSerGlnLysValThrThrAsn	200
Db	608	GAAGAAGCTATTAATCTATTAGGAAGAGGGGTTTTTATTTCACGAAGATTACCACTAT	667
OY	201	ProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrTrpGlyProAsnI1eMetThr	220
Db	668	CCAAACCTTAGGATCATCATGCTTAACACAAACTGTATCTACGGCCCAATATATATGACA	727
OY	221	LeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGlnSerThrLeuAsnAsnSer	240
Db	728	CTGAACAAGACTGACCCAGCCCAACAGTTTGAATGGCTAGAAAGTAACTTGAACAACCTCT	787
OY	241	GlnGlnIleAsnLysGlyLysValTyrI1IleAlaHisValI1ProValGlyTyrTrpLeuProSer	260
Db	788	CAGACAGATTAAGGAGAGGTGTATATCATACACATGTTCCAGGGGGTATCTCCACATCT	847
OY	261	SerGlnAsnI1eTrrAlaMetArgGlyTyrTyrAsnGlnLysLeuI1eAspI1ePheGln	280
Db	848	TCACAGAACATCACACGACATGAGGAATCTATATAGAAATGATAGATTTTTCAA	907
OY	281	LysTyrSerAspValI1eAlaGlyGlnPheTyrGlyHisThrHisArgAspSerI1eMet	300
Db	908	AAATACAGTAGTATGCATTTGACAGACAAATTTATGACACACTCACAGAGACAGATTATG	967
OY	301	ValLeuSerAspLysLysGlySerProValAsnSerLeuPheValAlaProAlaValThr	320
Db	968	GTTCTTTTCAGTAAAAAAGAAAGTCCAGTAATTTCTGTTGTGGCTCCCTGCTGTATACA	1027
OY	321	ProValLysSerValLeuGlnLysGlnThrAsnAsnProGlyI1eArgLysLeuPheGlnTyr	340
Db	1028	CCAGGGAAGATGTTTATGAAAAACAGCCACACATCTCTGATATACAGATCTTTCACTAT	1087
OY	341	AspProAlaArgAspTyrLysLeuLeuAspMetLeuGlnTyrTrpLeuAsnLeuThrGlnAla	360
Db	1088	GATCTCTGTGATTTAATTAATTTATGATATGTTGCAATTTACTTGAATCTCACAGAGCG	1147
OY	361	AsnLeuLysGlyGlnSerI1eTrpLysLeuGlnLysTyrI1eLeuThrGlnThrTyrAspI1e	380
Db	1148	AATCTAAAGGAGAGTCCATCTGGAACCTGGAGATATCTCCGACCCAGACTTACGACACTT	1207
OY	381	GlnAspLeuGlnProGlnLysSerLeuTyrGlyLeuAlaLysGlnPheTrilLeuAspSer	400
Db	1208	GAAGATTTGACCGCGAAGATTATATATGATTAATCTTAACCAATTTTACATCTAGACAGT	1267
OY	401	LysGlnPheI1eLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCys	420
Db	1268	AAGCAAGTTTAAATATCTACAAATTACTCTCTTGTGAGTTATGACACAGGTAAACATGT	1327
OY	421	AspLysThrCysLysAlaPheGlnI1eCysAlaI1eMetAsnLeuAspAsnI1eSerTyr	440
Db	1328	GATTAAGACATGTAAAGCCCTTTCAATTTGTGCAATTTATGAAATCTTGATTAATATTTCTAT	1387
OY	441	AlaAspCysLeuLysGlnLeuTyrI1eLysHisAsnTyr	453
Db	1388	GCAGATTGCTCCAAACAGCTTTATATATAAAGACAAATTAAC	1426

QY	81	lysaspserprocyrglnleuileuSera1aphesphel1e1yrsanserg1gln	100
Db	309	tgatattctccatnaccattattttgtcagcattgattttatttataaaattctgcgacaa	366
QY	101	glu1aserPheMet11etripThg1yaspserProh1svalProvalProgl1leu	120
Db	369	gaagatctttcatgatnrtggacaggggatvagccacctcatgttctctgaaccgaactc	428
QY	121	SerThrAspThrVal11leasval11eThraSmetThrThrhl1eg1nser1euphe	140
Db	429	tcaacagacactggttaataaATGTATATCACTAATATATGCAACCAACATTCAGAGCTCTTT	488
QY	141	Proas1eug1nval1PhePro1aleuG1yAsn1sasp1yrt1rProgl1naspG1nleu	160
Db	489	ccaaatctccaggttttccctgcctgggtrtcatatgcatattggccacaggaatcaactg	548
QY	161	SerVal1ThrSer1ySval1yTrAsn1a1a1aas1eul1eul1ySPro1rP1euaSp	180
Db	549	cctgtagtcaccacgtaaaAGTGTACAAATGcagtaCAAAcctctggaaacacatgctagat	608
QY	181	glu1gual11eSerThr1eua1xg1yG1yPhe1ySerG1n1ySval1ThrThraSn	200
Db	609	gaagaaGctattagactttaaGaaAAGGtggtttatttaccagaaattacactaat	668
QY	201	Proas1eua1rG11e1Ser1euaSnThraSn1eul1yrt1rG1yProas11eMetThr	220
Db	669	ccaaaccttagaatcatcagctaaACCAAAccttgtaCTACGgcccCAAAATATATGACA	728
QY	221	LeuaSn1yThraSpPro1a1aSnG1nPhel1u1rP1eug1uSerThr1euaAaAsnSer	240
Db	729	ctgaacaaAGactgcccacgccaacacgatttaAGctgtagaaatgtaCTGaaAACctCT	788
QY	241	glu1n1aSn1ySg1u1ySval1yrt11e1a1a1a1sval1ProvalG1yTr1eupProser	260
Db	789	cagcagaattaaAGGAGAGAGAGtGTATATCTACGACATgTCCAGtGGGGTATCTGCATCT	848
QY	261	SerG1naSn11eThra1aMet1ArgG1u1yrt1rYraSg1u1ySleu11easP11ePhelG1n	280
Db	849	tcacagaaCATcACAGCAATGAGAAATACATATATGAGAAATGATATATTTTTCAA	908
QY	281	lys1yTrSeraspval11e1a1g1yG1nPhel1yrtG1h1sThrh1a1yaspSer11eMet	300
Db	909	aaATCAcAGtGATGTcATTGcAGGACAAATTTATGACACACTcACACAGACAGCACTTATG	968
QY	301	Val1euserAsp1ySg1ySerProval1aSnSer1eupheVal1a1aProval1aVal1Thr	320
Db	969	gTtcttTCAgATRAAAAGAAAGAGTCCATTAATCTTGTtTGtGGCTCctGcGTGACA	1028
QY	321	Proval1yServal1leuG1u1ySg1nThraSnAsnProG1y11e1a1yG1eupPhelG1nTr	340
Db	1029	ccAGTGAAGAGCTTTTGAaaaaACAGACCAACATCTCGTATACAGCTGTTCAGAT	1088
QY	341	AspPro1a1yasp1yTr1e1e1e1e1e1e1e1e1e1yrt1r1e1e1e1e1e1e1ThrG1u1a	360
Db	1089	gATCTCGATTAATAAATATATGATATGTTGcAGTATATCTTGAATCTGACAGAGCG	1148
QY	361	Asn1eul1ySg1yG1uSer11e1rP1yS1eug1u1yrt11e1e1u1rG1nThr1yraSp11e	380
Db	1149	aatctraaAGGAGAGATCCATCTGAGAGCTGAGATATCTGACCCAGACCTTACGACAT	1208
QY	381	glu1aSp1eug1nProG1uSer1eul1yrtG1y1eua1a1ySg1nPhelThr111e1euaSpSer	400
Db	1209	gaAGATTtTGACCCGGAAGTTTATATGATTAAGCTAAACAATTTACATCTTACAGCT	1268
QY	401	lysG1nPhel11e1yTr1yTrAsn1yTrPhePheVal1Ser1yraSpSerSerVal1ThrCys	420
Db	1269	aaGcAGCTTATTAATTACTCAATTACTTCTTTGcAGTATGACAGCAGTGTAAcATG	1328
QY	421	Asp1yS1ThrCys1yS1a1aPhelG1n11eCys1a1a11eMetAsn1euaSpAsn11eSer1y	440
Db	1329	gATTAAGACATGTAAAGCCTTTCAgATTGTGCAATTATGAAATCTTGATTAATATTTCCAT	1388

Oy	421	AspIysThrCysIysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyr	444
Db	1329	GATTAAGACATGATTAAGGCCCTTCGATTGTGCAATTATGATATGATATTTCTAT	1385
Oy	441	AlaAspCysLeuIysGlnLeuTyrIleLeuHisAsnTyr	453
Db	1389	GCAATTGGCCTCAACAGACCTTTATATATTAACACAAATTAC	1427
RESULT 5			
ID	ADB90834	standard; cDNA; 1764 BP.	
AC	ADB90834;		
XX			
DE	04-DEC-2003	(first entry)	
XX			
DE	Human cDNA encoding hydrolase-like molecule, HHLM 5, INCYTE 1376382.		
KW	Human; hydrolase-like molecule; HHLM; cell proliferation disorder;		
KW	arteriosclerosis; atherosclerosis; bursitis; psoriasis; cancer;		
KW	autoimmune disorder; AIDS; Addison's disease;		
KW	adult respiratory distress syndrome; anaemia; asthma; diabetes mellitus;		
KW	ss; gene.		
XX			
OS	Homo sapiens.		
XX			
PN	US6518029-B1.		
XX			
PD	11-FEB-2003.		
XX			
PF	07-JUL-2000; 2000US-00612473.		
XX			
PR	06-FEB-1998; 98US-00013881.		
PA	(INCYTE) INCYTE GENOMICS INC.		
XX			
PI	Bandman O, Lal P, Hillman JI, Corley NC, Guegler KJ, Shah P;		
DR	WPI: 2003-742789/70.		
XX	P-PSDB; ADB90826.		
XX			
PT	New human hydrolase-like molecules, useful for treating or preventing		
PT	cell proliferation disorders (e.g. atherosclerosis or cancers) and		
PT	autoimmune disorders (e.g. AIDS, Addison's disease, anemia, asthma and		
PT	diabetes mellitus).		
XX			
XX	Example 6; Col 65-68; 55pp; English.		
PS			
XX			
CC	The invention relates to a new isolated polypeptide comprising a human		
CC	hydrolase-like molecule, termed HHLM-8 appearing as ADB90822 - ADB90829,		
CC	a naturally occurring polypeptide comprising a sequence which is at least		
CC	81% identical the HHLM, a biologically active fragment of an HHLM or an		
CC	immunogenic fragment comprising at least 15 contiguous amino acids. Also		
CC	included are a composition comprising an HHLM and an excipient, a method		
CC	for screening a compound as an agonist or antagonist of HHLM (by exposing		
CC	a sample comprising HHLM to a compound, and detecting agonist or		
CC	antagonist activity in the sample), a method for screening a compound		
CC	that specifically binds to HHLM (by combining HHLM with at least one test		
CC	compound, and detecting binding of HHLM to the test compound) and a		
CC	method for screening a compound that modulates the activity of HHLM. The		
CC	human hydrolase-like molecules (HHLM), agonists and antagonists useful		
CC	for treating or preventing cell proliferation disorders (e.g.		
CC	arteriosclerosis, atherosclerosis, bursitis, psoriasis, and cancers) and		
CC	autoimmune disorders (e.g. AIDS, Addison's disease, adult respiratory		
CC	distress syndrome, anaemia, asthma and diabetes mellitus). The HHLM		
CC	polypeptides are useful in preparing antibodies that specifically bind to		
CC	the polypeptides. Nucleic acids encoding HHLM are useful in generating		
CC	probes for mapping naturally occurring genomic sequences, in detecting		
CC	differences in the chromosomal location due to translocation or		
CC	inversion, and in screening libraries of compounds in drug screening		
CC	techniques. The present sequence encodes an HHLM of the invention.		
XX			

50	1764	BP: 537 A; 356 C; 344 G; 527 T; 0 U; 0 Other;
Alignment Scores:		
Pred. No.:	1,17e-223	Length: 1764
Score:	2422.00	Matches: 452
Percent Similarity:	99.78%	Conservative: 0
Best Local Similarity:	99.78%	Mismatches: 1
Query Match:	99.79%	Indels: 0
DB:	10	Gaps: 0
US-09-823-119B-1 (1-453) x ADB90834 (1-1764)		
QY	1	MetAlaLeuValArgAlaLeuValCysCysLeuLeuThrAlaTrpHisGlySerGly 20
DB	69	ATGGGGCTGGTGGGGGCACTGCTGCTGGCTGGCTGACTGCTGGGACTGGGACTGGCGCTCGCG 128
QY	21	LeuGlyLeuProValAlaProAlaGlyGlyArgAspProProProAlaIleGlyGlnPhe 40
DB	129	CTCGGGGCTGCCCGTGGCCGCCCGGACGGAGATCTCTCCCTCGGGCGATAGACAGTTT 188
QY	41	TrpHisValThrAspLeuHisLeuAspProThrTyriHisIleThrAspAspHisThrLys 60
DB	189	TGGCAGTGACTGACTTACACTTACAGCCCTACTTACCATGACATGACAGATGACACACAA 248
QY	61	ValCysAlaSerSerLysGlyValAlaAsnAlaSerAspProGlyProPheGlyAspValLeu 80
DB	249	GTGTGTGTTTCACTTAAAGGTGCAATGCTCCCAACCTGGCGCTTTGGAGATGTTCTG 308
QY	81	CysAspSerProTyGIleuIleLeuSerAlaPheAspPheIleLysAsnSerGlyGln 100
DB	309	TGTGATTTCTCCATTCACACTTATTTTGTGCAGATTTGATTTTATTAATAATCTGGACA 368
QY	101	GlyAlaSerPheMetIleTrpThrGlyAspSerProPheHisValProValProGlyLeu 120
DB	369	GAAGCATCTTTCATGATATGACAGAGGATAGCCACCTCATGTTCTGTACTGTAACTC 428
QY	121	SerThrAspThrValIleAsnValIleThrAsnMetThrThrIleGlnSerLeuPhe 140
DB	429	TCMAAGACACCTGTTATAATGTGATCACTAATATGACACACCACTCCAGAGTCTCTTT 488
QY	141	ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyTrpProGlnAspGlnLeu 160
DB	489	CCAAATCTCCAGGTTTTCCTGCGCTGGGTATCATGACTATTTGGCCACAGATCACTG 548
QY	161	SerValValThrSerLysValTyranalValAlaAsnLeuTrpLysProTrpLeuAsp 180
DB	549	CCTGTAGTCCACAGTAAAGTGTACATGACAGACCAACCTCTGGMAAACATGGCTGAGAT 608
QY	181	GlyGlyAlaIleSerThrLeuArgLysGlyGlyPheTySerGlnLysValThrThrAsn 200
DB	609	GAAGAGAGCTATTAAGTCTTAAAGAAAGGTGGTTTTTATTCACAGAAAGTTTCAACTAAT 668
QY	201	ProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyTyGIProAsnIleMetThr 220
DB	669	CCAAATCTTGGATATCATGCTTAAACCAAACTTGACTAGCGCCCAATATTAATAGACA 728
QY	221	LeuAsnLysThrAspProAlaAsnGlnPheGlyTrpLeuGlySerThrLeuAsnAsnSer 240
DB	729	CTGAACAAAGACTGACCCAGCCCAACCAAGTTTGATGGCTGAAAGATACATTGAACAACTCT 788
QY	241	GlyGlnAsnLysGlyLysValTyriIleIleAlaHisValProValGlyTyriLeuProSer 260
DB	789	CAGCAGAAATTAAGAGAAAGGTGTATATCATAGACACATGTTCACGTGGGATCTGCCATCT 848
QY	261	SerGlnAsnIleThrAlaMetArgLysTyTyranGlyLysLeuIleAspIlePheGln 280
DB	849	TACAGCAACATACAGCAATGAGAGAAATCTTAATAGAAATTTGATATATTTTTCAA 908
QY	281	LysTySerAspValIleAlaGlyGlnPheTyTyriHisThrHisArgAspSerIleMet 300
DB	909	AAATACAGTGAATGCTATTTGCAGACAACTTTTATGGACACACTGCACGAGACAGCATTAATG 968
QY	301	ValLeuSerAspLysGlySerProValAsnSerLeuPheValAlaProAlaValAlaThr 320

Db	969	GTCTCTTCAGATTAATAAAGGAGAGTCACGTAATAATCTTGTGTGGCTCTGCTGTACCA	1028		
Qy	321	ProValIySseSerValIleuGluIuLySGlnThrAsnAsnProGlyIleArgLeuPheGlnThr	340		
Db	1029	CCAAGTGAAGAGCTGTTTATGAAAAACAGACCAACAATCTCGTATACAGCTGTTTCAGAT	1088		
Qy	341	AspProArgAspThrLyLeuLeuAspMetLeuGlnThrLyLeuAsnLeuThrGluAla	360		
Db	1089	GATCCTCGTGATTTAATTAATTTATGGAATATGTTGCAGTATTAATCTGAATCTGACAGAGCG	1148		
Qy	361	AsnLeuLySGIyGluSerIleThrLyLeuGlnIuThrIleLeuThrGlnThrThrAspIle	380		
Db	1149	AATCTTAAAGGAGAGAGTCATCTGGAAGCTGGAAGATATACCTGACCCACCACTTACGACATT	1208		
Qy	381	GluAspLeuGlnProGluSerLeuThrGlyLeuAlaLySGlnPheThrIleLeuAspSer	400		
Db	1209	GAAAGTTTGCAGCCGGAAGTTTATATGATTAAGCTTAAACAATTTACAACTCTTGACAGT	1268		
Qy	401	LySGlnPheIleLySerThrAsnThrPhePheValSerThrAspSerSerValThrCys	420		
Db	1269	AAGCAGTTTATTAATAATACTACATTAATCTCTTGTGAGTTATGACAGCAGTGTAACATGT	1328		
Qy	421	AspLyThrCysLyGalaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerThr	440		
Db	1329	GATTAAGACATGATTAAGGCCCTTCAGATTTGTGCATTAATGAATCTTGATTAATATTTCTCAT	1388		
Qy	441	AlaAspCysLeuLySGlnLeuThrIleLySHisAsnThr	453		
Db	1389	GCAGATTGCTCTCAACAGCTTTATATTAAGACCAATTAC	1427		
RESULT 6					
ADJ45508	ID ADJ45508 standard; cDNA, 1768 BP.				
XX	ADJ45508;				
AC					
XX	ADJ45508;				
DT	06-MAY-2004	(first entry)			
XX					
DE	cDNA encoding LXR-ligand induced transcript seq id 39.				
XX					
KW	LXR; liver X receptor; cholesterol; gallstone; atherosclerosis;				
KW	lipid storage disease; obesity; diabetes; hypercholesterolaemia;				
KW	LXR-ligand induced 1; LXR1; human; LXR-ligand induced transcript;				
KW	LXR regulated gene; ss; gene.				
OS	Homo sapiens.				
XX					
PN	US2004023276-A1.				
XX					
PD	05-FEB-2004.				
XX					
PF	02-MAY-2003; 2003US-00429160.				
XX					
PR	03-MAY-2002; 2002US-0377714P.				
XX					
PA	(WARD/) WARD T R.				
PA	(MAOM/) MAO M.				
PA	(LINS/) LINSLEY P S.				
PA	(LUND/) LUND E.				
XX					
PI	Ward TR, Mao M, Linsley PS, Lund E;				
XX					
DR	WPI; 2004-224687/21.				
XX					
DR	P-PSDB; ADJ45509.				
XX					
PT	New purified liver X receptor (LXR) nucleic acids, useful for diagnosing				
PT	a disease involving LXR activity, such as cholesterol gallstones,				
PT	atherosclerosis, lipid storage diseases, obesity, diabetes, or				
PT	hypercholesterolemia.				
XX					
PS	Example 1; SEQ ID NO 39; 141bp; English.				
XX					

The invention describes a purified nucleic acid comprising a fully defined sequence of 1586 bp (SEQ ID NO: 1) as given in the specification, or its complement. The methods and compositions are useful for diagnosing a disease or disorder involving LXR (liver X receptor) activity in a sample by detecting an increase or decrease in the transcript level relative to the amount present in an analogous sample from a subject not having the disease or disorder or not subjected to therapy, wherein the disease or disorder is cholesterol gallstones, atherosclerosis, lipid storage diseases, obesity, diabetes, or hypercholesterolaemia. They are also used to identify a compound that changes LXR activity, wherein the compound changes the estimated level of LXR activity in a sample from the subject contacted with the compound relative to the estimated level of LXR activity in an analogous sample from the subject not contacted with the compound. This sequence encodes an LXR regulated protein.

Sequence 1768 BP; 540 A; 358 C; 346 G; 524 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	Length:	Matches:
1.17e-223	1768	452
Score:	2422.00	Mismatches: 0
Percent Similarity:	99.78%	Indels: 1
Best Local Similarity:	99.78%	Gaps: 0
Query Match:	99.79%	

US-09-823-119B-1 (1-453) x ADJ45508 (1-1768)

QY 1 MetalAlaValArgAlaLeuValCysCysLeuLeuThrAlaTrpHisCysArgSergly 20
Db ATGGGCGTGGTGCGGCACCTGTCTGCTGCCCTGACTGCTCCAGCATCGCCGCTCCGCGC 137
QY 21 LeugLYleuProValAlaProHlaGlyIArgAanProProProAlaIlegIynphe 40
Db CTCGGGCTGCGCCGTGGCCGCCGACAGGCGAGAAATCCCTCCGCGCATAGACAGTTT 197
QY 41 TrpHisValThraPleunHisLeuaspProthyryHisileThraSpasphistrLyvs 60
Db TGCGCATGTGACGACTTACCTTAACCTTACCATTACCAATCACAGATCACACACAAA 257
QY 61 ValCysAlaSerSetLygLYalaamnlaserAanProglyProPhelgIyaspVllaau 80
Db GTGTGTGCTCACTCAAAGGTGCAAATGCTCCAACCTCGGSCCTTTTGAGATGTCTG 317
QY 258 GTGTGTGCTCACTCAAAGGTGCAAATGCTCCAACCTCGGSCCTTTTGAGATGTCTG 317
QY 81 CysAspSerProTYGIleuIleLeuSerAlaPheaspPheileysAnserGlygin 1000
Db TGTGATTCCTCAATCAACTTATTTTTCAGCATTTGATTTTATATAAAATTCGACAA 3777
QY 101 GluaIaserPheMetileTrpThrIyaspSerProFohisValProvalProglueu 120
Db GAAGCATCTTTCATGATATAGACAGAGGATAGCCACCTCATGTTCTCTACTCGAACATC 4378
QY 121 SerThraapThralleasnValillethrasmetThrThrillegInserLeupe 140
Db TCMAACAGACACTGTATAATGTGTATCTAATATAGACAACACCAATCCAGAGTCTCTT 497
QY 141 ProAntleuglnValPheProhlaLeugIyaSnhlaspyTyTriProglinsapglneu 160
Db CCNAATCTCCAGATTTTCCCTGCGCTGGGTATTCATGACTATTTGGCCACAGATCACTG 557
QY 161 SerValalThSerLyvValTyranmlavalalasnleuTrplysProtTrpleuasP 180
Db CCTGTAGTCACCAAGTAAGTGTACATGACAGTAGCAAACTCTCGAAAAACATGGCTAGAT 617
QY 181 GlugluAlalleSerThreulgylsglygIepheryrSerglnlyValThrThraan 200
Db GAAGAAGCTATTAGTACTTAAAGGAAGGTGGTTTTTATTCACAGAAAGTTCAACTAAT 677
QY 201 ProAntleuArglleIleSerleuasnThrasnleutyryTYGIProasnIlemetThr 220
Db CCAAACTTAgGATATCATGTTAAACACAAACTGTACTACGGCCCAATTTAATGACA 737
QY 221 LeuanlyThraSPProAlaasnGlmphegiutrpLeuGluseThreunsnnsenS 240

Db	738	CTGAACAAGACTGACCCAGCCACCAACGTTGAATGGCTTAGAAAGTACATTGAACAACCTCT	797
OY	241	GIINGIaenLyuSGIuLyuValTYrIlelleaLahSvalProValGIYrIleuProser	260
Db	798	CAGCAGAAATTAAGGAAGAGGTGTATATCATACAGACATGTTCCAGTGGGGATCTGCACATCT	857
OY	261	SerGIaenLileThIaMeKArgGIuTYrTYraNGIuLyLeuLleAspIlePheGln	280
Db	858	TCACAGAAACATCACAGCAATGAGAAATCTATTAATGAGAAATGTATATATTTTTCAA	917
OY	281	LYSTYrSerAspValIlealaGIyGlnPheTYrGIyHISthrHISArgAspserIleMet	300
Db	918	AAATACAGATGATGTCATTGCAGACGAATTTATATGACACACTCAGACAGACAGCAATTATG	977
OY	301	ValLeuSerAspLyLyLyGIySerProValaenSerLeuPheValAlaProAlaValThr	320
Db	978	GTTCCTTTAGATTAATAAAAGGAAGTCCAGTAATATCTTGTTGTGTGGCTCTGCTGTATCA	1037
OY	321	ProValLySerValLeuGIuLySGIlnThraenAsnProGIYIleArgLeuPheGlnTYr	340
Db	1038	CCAGTGAAGAGGTGTTTAGAATAAACAGACCAACATCTCGGTATCAGACTGTTCAAGTAT	1097
OY	341	AspProArgAspTYrIlyLeuLeuAspMetLeuGlnTYrTYrLeuAsnLeuThrGIuAla	360
Db	1098	GATCCTCGTGAATTAATAATTAATGAGTATGTTCGAGTATTACTTGAATCTGACAGAGGGC	1157
OY	361	AsnLeuLySGIyGIuSerIleTrpLyLeuGIuTYrIleLeuThGIlnThTYrAspIle	380
Db	1158	AATCTTAAGGGAGAGAGTCCATCTGGAGCTGGAGTATATCTTCAACCCAGACCTTAGACATTT	1217
OY	381	GIuAspLeuGlnProGIuSerLeuTYrGIyLeuAlaLyGlnPheThrIleLeuAspSer	400
Db	1218	GAAAGATTTCAGACCCGAAAGTTTATATGATTAGCTTAACAAATTTATACATCTTAACAGCT	1277
OY	401	LySGInPheIleLySTYrTYraSnTYrPhePheValSerTYrAspSerSerAlaThrCys	420
Db	1278	AAGCAGTTTATTAATAACTACACATTACTCTTGTGAGTTAGACAGCAGTATAACAGT	1337
OY	421	AspLySThrCysLySAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTYr	440
Db	1338	GATAAGACATGTAAAGGCCCTTTCAGATTGTGCAGATTATGAATCTTGATATATTTCTCAT	1397
OY	441	AlaAspCysLeuLySGInLeuTYrIleLySHISAsnTYr	453
Db	1398	GCAGATTGCCCTCAACAGCTTTATATTAAGCAACAATTATC	1436

RESULT 7	
AA862765	
ID	AA862765 standard; cDNA; 1783 BP.
XX	
AC	AA862765;
XX	
DT	14-FEB-2002 (first entry)
XX	
DE	cDNA sequence #552 encoding novel human secreted protein.
XX	
KM	Human secreted protein; hyperproliferative disorder; autoimmune disorder;
KM	immune deficiency disorder; blood disorder; inflammatory disorder;
KM	infectious disorder; gene therapy; antimicrobial; hepatotropic;
XX	immunosuppressive; antineumatic; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200177291-A2.
XX	
PD	18-OCT-2001.
XX	
PF	29-MAR-2001; 2001WO-US010485.
XX	
PR	06-APR-2000; 2000US-0195604P.
XX	
PA	(GEMY) GENETICS INST INC.
XX	

PI Wong GG, Clark HF, Fechtel K, Agostoino MJ, Howes SH, Resnick RJ;
PI Gutukota K, Graham JR;
XX
XX WPI, 2002-010900/01.
XX
XX
XX New polynucleotides encoding secreted proteins useful for treating e.g
PI asthma, HIV and Crohn's disease.
XX
XX Claim 1; Page 356; 331pp; English.

CC The present invention relates to the isolation of novel cDNA sequences
CC which encode human secreted proteins. The cDNA sequences have been
CC derived from a variety of human tissues. The invention also provides a
CC method for producing proteins from these polynucleotide sequences. The
CC proteins are useful for identifying compounds that modulate their
CC activity and production, and the cell is also useful for identifying
CC compounds that modulate expression of the polynucleotide sequences
CC encoding the secreted proteins. The sequences of the invention are useful
CC for treating diseases such as hyperproliferative disorders (e.g. cancer),
CC immune deficiency disorders (e.g. severe combined immunodeficiency
CC (SCID)), autoimmune disorders (e.g. multiple sclerosis), blood disorders
CC (e.g. thrombocytopaenia), inflammatory disorders (e.g. arthritis) and
CC infectious disorders (e.g. hepatitis). The polynucleotide sequences of
CC the invention are also useful in gene therapy. A5682214-A5682838
CC represent the cDNA sequences of the invention that encode for novel human
CC secreted proteins
XX
XX Sequence 1783 BP; 523 A; 376 C; 348 G; 536 T; 0 U; 0 Other;
SQ

Alignment Scores:	
Pred. No.:	8.77e-223
Scores:	2413.00
Percent Similarity:	99.56%
Best Local Similarity:	99.56%
Query Match:	99.42%
DB:	6
	Gaps: 0
Length:	1783
Matches:	451
Conservative:	0
Mismatches:	2
Indels:	
	Gaps: 0

US-09-823-119B-1 (1-453) x AAS62765 (1-1783)

OY	1	MetAlaLeuValAlaArgAlaLeuValCysCysLeuLeuThrAlaTPrHisCysValGserGly	20
Db	113	ATGGCCCTGGTGGGGCACTCGTCGTGCTGTGGATGGCTTGGCACTGGCTGGCCGCTCGGCG	172
OY	21	LeuGlyLeuProValAlaProAlaGlyGlyArgAsnProProProAlaIleGlyGlnPhe	40
Db	173	CTGGGCGTGGCGGTGGCGCCCGCAGCGGCAAGAAATCTCTCCGCGGATRGACAGTTT	232
OY	41	TPrHisValThrAspLeuHisLeuAspProThrTyHisIleThrAspAspHisIleHis	60
Db	233	TGGCATGTGATGCATTAACCTTAAGCCCTACTTACCAATCAAGATGACCAACACAAA	292
OY	61	ValCysAlaSerSerIleGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValLeu	80
Db	293	GTTGTGGCTTCACTTAAGGTGGCAATCTCCCAACCTGGCGCTTTTGAAGATGTTTCG	352
OY	81	CysAspSerProTyGlnLeuIleLeuSerAlaPheAspPheIleLeuAsnSerGlyGln	100
Db	353	TGTGATTTCCATATCAACTATTTTGTGCAGCATTTGATTTATTAATAAATTTCTGGACA	412
OY	101	GluAlaSerPheMetIleTPrHisGlyAspSerProProHisValProValProGlnLeu	120
Db	413	GAGCATCTTTCATGATATGACAGGGGATGACCACTCATGTTCTGTACCTGAATC	472
OY	121	SerThrAspThrValIleAsnValIleHisAsnMetThrThrThrIleGlnSerLeuPhe	140
Db	473	TCAACGAGACACTGTTATAAATGTGATCACTAATATGACAAACACCAATCCAGAGTCTTTT	532
OY	141	ProAsnLeuGlyValPheProAlaLeuGlyAsnHisAspTyTyrTPrProGlnAspGlnLeu	160
Db	533	CCAAATCTCAAGTTTTCCTTCGCTGGGTATATGACATCTTGGCCACAGATCAACTG	592
OY	161	SerValValThrSerIleValTyrAsnAlaValAlaAsnLeuTPrIleProTPrLeuAsp	180

Db 593 CCTGAGTACACAGTAAGTATACATGACAGCAAACTCTGGAACCATGCTAGAT 652
 Qy 181 |G|U|G|U|A|A|I|S|E|T|H|L|E|U|A|G|U|G|U|P|H|E|T|Y|S|E|S|G|U|L|V|A|T|H|T|H|S|N 200
 Db 653 GAAAGAGCTATTAGACTTATTAAGAAAGGTGGTTTATTCACAGAAAGTTACACTAT 712
 Qy 201 |P|H|A|N|L|E|U|A|G|I|L|E|S|E|T|H|L|E|U|A|N|T|H|S|L|E|U|T|Y|T|G|U|P|H|E|T|H| 220
 Db 713 CCAACCTTAGATCATCATGCTTAACACAACTTGTCTACGCCCAAAATTAATGCA 772
 Qy 221 |L|E|U|A|N|Y|T|H|A|P|P|H|A|S|N|G|U|L|P|H|E|G|U|T|P|L|E|U|S|E|T|H|L|E|U|A|N|S|E| 240
 Db 773 C|T|G|A|A|C|A|A|G|A|C|T|C|C|C|A|C|C|A|G|T|T|G|A|A|T|G|C|T|A|G|A|A|G|T|A|C|A|C|A|C|T| 832
 Qy 241 |G|I|N|G|I|N|L|E|U|S|G|U|L|V|A|T|Y|T|L|E|I|L|E|A|H|S|V|A|P|R|O|V|A|G|U|T|Y|L|E|U|P|H|E|T|H| 260
 Db 833 C|A|G|A|G|A|T|A|G|A|G|A|G|G|T|A|T|A|T|C|A|T|A|C|A|C|A|G|T|G|G|G|T|A|T|C|G|C|A|C|T| 892
 Qy 261 |S|E|S|I|N|A|N|I|E|T|H|A|L|A|M|E|T|A|R|G|U|T|Y|T|A|N|G|U|L|V|S|L|E|U|I|E|A|S|P|I|L|E|P|H|E|G|I|N| 280
 Db 893 T|C|A|C|G|A|A|C|A|T|C|A|C|G|C|A|T|A|G|A|A|T|C|T|T|A|T|G|A|A|A|T|G|A|T|A|T|T|T|T|C|A| 952
 Qy 281 |L|Y|S|Y|S|E|A|P|V|A|I|I|E|A|G|I|V|G|I|N|P|H|E|T|Y|G|I|S|H|H|I|S|A|R|G|A|S|S|E|T|L|E|W|E|T| 300
 Db 953 A|A|T|A|C|A|G|T|G|A|T|G|C|A|G|A|C|A|A|T|T|T|A|T|G|A|C|A|C|A|C|T|C|A|C|A|G|A|C|A|G|C|A|T|A|T|G| 1012
 Qy 301 |V|A|L|L|E|U|S|E|A|P|P|H|V|S|G|U|S|E|T|P|R|O|V|A|L|N|S|E|T|H|L|E|U|P|H|E|V|A|I|A|P|R|O|V|A|I|A|T|H| 320
 Db 1013 G|T|T|T|T|C|A|G|T|A|A|A|A|A|G|A|A|G|C|A|G|T|A|A|T|T|G|T|G|T|G|G|C|C|T|G|T|G|T|A|C|A| 1072
 Qy 321 |P|R|O|V|A|L|Y|S|E|S|E|V|A|L|L|E|U|S|G|U|L|N|H|S|A|N|P|R|O|G|I|L|E|A|R|G|U|P|H|E|G|I|N|T|Y| 340
 Db 1073 C|C|A|G|T|A|G|A|G|T|T|T|T|G|A|A|A|A|C|A|G|C|A|C|A|C|A|C|T|G|G|T|A|C|A|G|C|T|G|T|T|C|A|G|A|T| 1132
 Qy 341 |A|S|P|P|H|A|S|E|A|P|Y|T|Y|L|S|L|E|U|A|S|P|H|E|U|G|I|N|T|Y|T|Y|L|E|U|A|N|L|E|U|T|H|G|U|A| 360
 Db 1133 G|A|T|C|C|T|G|G|T|A|T|T|A|A|T|T|A|T|T|G|A|T|A|T|T|G|C|A|G|T|A|T|C|T|G|A|T|C|A|C|A|G|A|G|G|C|G| 1192
 Qy 361 |A|S|N|L|E|U|S|G|U|S|E|T|I|E|T|P|L|S|L|E|U|G|U|T|Y|T|L|E|U|T|H|G|I|N|T|H|T|Y|A|S|P|I|L|E 380
 Db 1193 A|A|T|T|A|A|G|G|A|G|G|A|G|T|C|A|T|T|G|A|A|G|T|G|A|G|A|T|A|C|C|G|A|C|C|A|C|C|A|C|C|T|A|G|A|C|A|T|T| 1252
 Qy 381 |G|U|A|S|L|E|U|G|I|N|P|R|O|G|I|S|E|T|Y|T|G|I|L|E|U|A|I|A|L|Y|S|G|I|N|P|H|E|T|H|I|L|E|U|A|S|P|E| 400
 Db 1253 G|A|A|G|T|T|G|C|A|G|C|C|G|A|A|G|T|T|A|T|G|A|T|T|A|G|C|T|T|A|A|C|A|A|T|T|T|A|C|A|T|C|T|G|A|C|A|G|T| 1312
 Qy 401 |L|Y|S|G|I|N|P|H|E|I|L|E|Y|S|Y|T|Y|A|S|N|T|Y|P|H|E|V|A|S|E|T|Y|A|S|P|S|E|S|E|V|A|I|T|H|C|Y|S| 420
 Db 1313 A|A|G|C|A|G|T|T|A|T|A|A|A|T|A|C|A|A|T|T|A|C|T|T|T|G|A|G|T|A|T|G|A|C|A|G|A|G|T|A|C|A|T|G|T| 1372
 Qy 421 |A|S|P|Y|S|H|T|C|Y|S|V|S|A|I|A|P|H|G|I|N|I|E|C|Y|A|A|I|I|E|W|E|T|A|N|L|E|U|A|S|P|A|N|I|L|E|S|E|T|Y| 440
 Db 1373 G|A|T|A|G|A|C|A|T|T|A|A|G|C|C|T|T|C|A|G|T|T|G|C|A|T|T|A|T|G|A|A|T|C|T|T|G|A|T|A|A|T|T|T|C|C|A|T| 1432
 Qy 441 |A|L|A|S|P|C|Y|S|L|E|U|S|G|I|N|L|E|U|T|Y|T|L|E|Y|S|H|S|A|N|T|Y| 453
 Db 1433 G|C|A|G|T|T|G|C|T|C|A|A|C|A|C|C|T|T|A|T|A|A|G|C|A|A|T|T|A|C| 1471
 RESULT 8
 AAS94849 ID AAS94849 standard; DNA; 1746 BP.
 XX AAS94849;
 AC AAS94849;
 XX 14-FEB-2002 (first entry)
 DT
 XX Human DNA sequence #104 expressed during foam cell differentiation.
 DE
 XX Human; foam cell differentiation; atherosclerosis; cerebral stroke;
 KW cardiovascular disorder; coronary artery disease; gene therapy; ds.
 XX
 OS Homo sapiens.
 XX

FN W0200177389-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX 04-APR-2001; 2001WO-US011128.
 PF
 XX 05-APR-2000; 2000US-0195106P.
 PR
 XX (INCY-) INCYTE GENOMICS INC.
 PA
 XX Shiffman D, Somogyi R, Lawn R, Seilhamer J, Porter GJ, Mikita T,
 PI Tal J;
 PI
 DR WPI; 2002-010925/01.
 XX
 XX Composition useful for diagnosis of conditions, disorders or diseases
 PT associated with atherosclerosis, comprises several polynucleotides that
 PT are differentially expressed in foam cell development.
 XX
 XX Claim 1; Page 156; 315pp; English.
 XX
 CC The present invention relates to the isolation of human polynucleotide
 CC sequences that are differentially expressed during foam cell
 CC differentiation. The polynucleotide sequences of the invention or a
 CC composition comprising these polynucleotides are useful as a high
 CC throughput method for detecting altered expression of one or more
 CC polynucleotides in a sample. The polynucleotides can be used in the
 CC diagnosis of disorders associated with foam cell development such as
 CC atherosclerosis, cerebral stroke, and cardiovascular disorders such as
 CC coronary artery disease. The polynucleotide sequences can also be used as
 CC PCR primers and probes. The polynucleotides of the invention are also
 CC useful in gene therapy. AAS94746-AAS95021 represent the human
 CC polynucleotide sequences of the invention which are differentially
 CC expressed during foam cell differentiation
 XX
 SQ Sequence 1746 BP; 521 A; 356 C; 342 G; 527 T; 0 U; 0 Other;
 Alignment Scores:
 Score: 2.07e-222 Length: 1746
 Pred: 2409.00 Matches: 452
 Percent Similarity: 99.56% Conservative: 0
 Best Local Similarity: 99.56% Mismatches: 1
 Query Match: 99.26% Indels: 1
 DB: Gaps: 0
 US-09-823-119B-1 (1-453) x AAS94849 (1-1746)
 Qy 1 |M|E|A|L|E|U|A|V|A|A|G|A|L|E|U|V|A|I|C|Y|S|L|E|U|L|E|U|T|H|A|T|P|H|I|S|C|Y|A|S|E|S|G|I| 20
 Db 69 |A|T|G|C|G|C|T|G|G|G|G|C|G|C|A|C|T|T|C|G|T|C|T|G|C|T|G|A|C|T|G|C|G|G|C|A|C|T|G|C|C|G|G| 128
 Qy 20 |Y|L|E|U|G|I|L|E|U|P|R|O|V|A|I|A|P|R|O|A|G|I|G|I|Y|A|G|A|S|N|P|R|O|P|R|O|A|I|I|E|G|I|N|P|H| 40
 Db 129 |C|C|T|G|G|G|C|T|G|C|C|G|G|C|C|G|C|G|C|G|C|G|C|G|A|A|T|C|T|C|C|G|C|G|A|T|A|G|C|A|G|T|T| 188
 Qy 40 |E|T|P|H|S|V|A|T|H|P|S|L|E|U|E|H|I|S|L|E|U|A|P|P|H|T|H|T|Y|H|I|G|I|L|E|H|P|H|S|A|P|H|I|S|T|H|Y| 60
 Db 189 |T|T|G|C|A|T|G|A|C|A|C|G|A|C|T|T|A|C|T|T|A|G|C|C|T|A|C|T|T|A|C|A|T|C|A|A|T|G|A|G|C|A|C|A|A| 248
 Qy 60 |S|V|A|C|Y|A|L|S|E|S|E|S|E|T|Y|S|G|I|A|A|A|A|A|S|E|A|S|P|R|O|G|I|P|R|O|H|E|G|I|A|S|P|V|A|L|E| 80
 Db 249 |A|G|T|G|T|G|C|T|T|C|A|T|A|A|A|G|G|G|C|A|A|T|G|C|T|C|C|A|A|C|C|G|G|C|C|T|T|T|G|A|A|G|A|T|G|T|C|T| 308
 Qy 80 |U|C|Y|A|S|P|S|E|P|R|O|T|Y|G|I|N|L|E|U|I|L|E|U|S|E|A|I|A|P|H|S|P|H|E|I|L|E|Y|S|A|N|S|E|S|G|I|Y|G|I| 100
 Db 309 |G|T|G|A|T|T|C|C|A|T|A|C|A|C|T|T|A|T|T|T|G|C|A|G|C|A|T|T|G|A|T|T|T|A|A|A|A|T|T|C|G|A|C|A| 368
 Qy 100 |N|G|U|A|L|S|E|S|P|H|E|T|I|E|T|P|H|R|G|I|A|S|P|S|E|P|P|R|O|H|I|S|V|A|P|R|O|V|A|I|P|R|O|G|I|U|E| 120
 Db 369 |A|G|A|G|A|C|A|T|T|T|C|A|T|G|A|T|A|G|A|C|A|G|G|A|G|A|G|C|C|A|C|C|T|C|A|T|G|T|C|T|G|A|C|T|G|A|C|T| 428
 Qy 120 |U|S|E|T|H|A|S|P|H|T|H|V|A|I|L|E|A|N|V|A|I|L|E|T|H|A|S|M|E|T|H|T|H|I|L|E|G|I|N|S|E|T|H|L|E|U|P|H| 140

```

Db      429 CTCAACAGACACGTATTAATGATCATTAATATGACCAACACCATCCAGACTCTT 488
Qy      140 ePrAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTrpProGlnAspGlnLe 160
Db      489 TCCAAATCTCCAGGATTTTCCCTGGCTGGTAATCATGACTATTGGCCACAGGATCACT 548
Qy      160 uSerValValThrSerIysValTyrAsnAlaValAlaAsnLeuTrpLysProTyrPLeuAs 180
Db      549 GCCGTGATGTCACCGAATAAGTGTACATGCGATGCAAACTCTGGAAACCATGGCTAGA 608
Qy      180 pGluGlnAlaIleSerThrLeuArgLyGlyGlyPheTyrSerGlnLysValThrAs 200
Db      609 TGAAGAAGCTATAGTACTTAAAGAAAGGTGTTTATTCACAGAAAGTTACACTAA 668
Qy      200 nProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrTyrGlyProAsnIleMetTh 220
Db      669 TCCAAACCTTAGATCATCACTGCTAAACACAACTTGACTACAGCCCAATATATAAGAC 728
Qy      220 rLeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGlnSerThrLeuAsnAsn 240
Db      729 ACTGAAACAAGCTAGACCCAGCAACAGTTGGAATGGCTAGAAAGTACATTGAACAATC 788
Qy      240 rGlnGlnAsnLysGlnLysValTyrIleIleAlaHisValProValGlyTyrLeuProSe 260
Db      789 TCACAGAAATAGAGAGAAAGGTGTATCATATGACACATGTTCCAGTGGGTATCTGCATC 848
Qy      260 rSerGlnAsnLysThrIleMetArgGluTyrTyrAsnGlnLysLeuIleAspIlePheG 280
Db      849 TTCACAGAACTCAGCATAGAGAAATGACTAATATGAAATGATAGATATTTTCA 908
Qy      280 nLysTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAspSerIle 300
Db      909 AAAATACAGTATGATGCATTCAGAGACAAATTTATGACACACTCAGACAGACACATTA 968
Qy      300 tValLeuSerAspLysGlySerProValAsnSerLeuPheValAlaProAlaValTh 320
Db      969 GGTTCCTTCAGATTAATAAAGAGAGAGCCAGTAATCTTGTGGTCTCTGCTGTTAC 1028
Qy      320 rProValLysSerValLeuGlnLysGlnThrAsnAspProGlyIleArgLeuPheGlnT 340
Db      1029 ACCAGTGAAGAGTGTGTAAGAAACAGACCAACAACTCTGATTCAGACTGTTTCAGTA 1088
Qy      340 rAspProArgAspTyrLysLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGlu 360
Db      1089 TGATCCTCGTATTATTAATATTGATATGTCAGATATTACTTGATTCAGACAGAGGC 1148
Qy      360 aAsnLeuLysGlyGlnSerIleTyrLysLeuGlnTyrIleLeuThrGlnThrTyrAsp 380
Db      1149 GAATCTAAAGGAGAGTCCATCTGGAAGCTGGAATATCTCGAACCCAGACTTCAGCAT 1208
Qy      380 eGluAspLeuGlnProGlnSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAspSe 400
Db      1209 TGAAGATTGACGCGGAAAGTTATATGATAGCTTAACAAATTTACAACTCTAGACAG 1268
Qy      400 rLysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCy 420
Db      1269 TAAACAGTTTATAAATATCTACATTAATCTTTGTGAGTTATAGACAGCACTGTAACTG 1328
Qy      420 sAspLysThrCysLysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTy 440
Db      1329 TGATTAAGCATGTAAAGCCCTTCAGATTGTGCAATATATGAAATCTTGATATATTTCTTA 1388
Qy      440 rAlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453
Db      1389 TGCAGATTGCTCAACAGCTTTATATTAAGCAACAATTAC 1428

```

```

RESULT 9
ID ADF81833 standard; DNA; 2505 BP.
AC ADF81833;
XX
XX 26-FEB-2004 (first entry)

```

```

XX      XX      Leukaemia-related DNA sequence #2389.
Db      DE      Leukaemia-related DNA sequence #2389.
XX      KM      Cytostratic; Gene therapy; leukaemia; ss.
XX      OS      Unidentified.
XX      EN      WO2003039443-A2.
XX      PD      15-MAY-2003.
XX      XX      04-NOV-2002; 2002WC-EP012303.
XX      PF      05-NOV-2001; 2001EP-00126244.
XX      PR      30-APR-2002; 2002EP-00009758.
XX      PA      (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
XX      PA      (VYLJ-) UNIV LUDWIG MAXIMILIANS.
XX      PA      (HAFE/) HAFERLACH T.
XX      PA      (SCHO/) SCHOCH C.
XX      PA      (KERN/) KERN W.
XX      PI      Haferlach T, Schoch C, Kern W, Kohlmann A, Schmittger S, Dugas M,
XX      PI      Elis R, Bross B, Mergenthaler S,
XX      DR      WPI; 2003-505037/47.
XX      PT      Determining the subtype of leukemia cells and whether a patient sample
XX      PT      contains leukemia cells or other cells; useful for treating leukemia,
XX      PT      comprises determining the expression profile of a group of markers in a
XX      PT      patient sample.
XX      PS      Disclosure; SEQ ID NO 2389; 2938bp; English.
XX      CC      The present invention relates to a method (M1) for determining the
XX      CC      subtype of leukemia cells and whether a patient sample contains
XX      CC      leukemia cells. The method comprises determining the expression profile
XX      CC      of a group of markers in a patient sample. The method is useful for
XX      CC      determining the presence of leukemia cells, its types or subtypes, and
XX      CC      for the preparation of a medicament for treating leukaemia.
XX      SQ      Sequence 2505 BP; 730 A; 537 C; 482 G; 737 T; 0 U; 19 Other;

Alignment Scores:
Pred. No.:      5,7e-217      Length:      2505
Score:          2355.00      Matches:      445
Percent Similarity: 98.02%      Conservative: 0
Best Local Similarity: 98.02%      Mismatches: 8
Query Match:      97.03%      Indels:      1
DB:              10      Gaps:      0

US-09-823-119B-1 (1-453) x ADF81833 (1-2505)
Qy      1      MetAlaLeuValAlaValAlaLeuValCysCys-LeuLeuThrAlaTrpHisCysArgSerG 20
Db      590      ATGGCGCTGGTGGCGCGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 649
Qy      20      yLeuGlyLeuProValAlaProAlaGlyGlyATGAsnProProProAlaIleGlyGlnPh 40
Db      650      CCTGGGCTGCGCGTGGCGCGCGAGGCGGAGGAAATCTCTCCGCGCATAGGNAAGTT 709
Qy      40      eTrpHisValThrAspLeuHisLeuAspProThrTyrHisIleThrAspAspHisThrTy 60
Db      710      NTNNNATGATGACTGACTTACACTTAAGCCCTACTTACATCAATCAATGACATGACACAAA 769
Qy      60      sValCysAlaSerSerLysGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValle 80
Db      770      AGTGTGTCTTCAATCTAAAGGTGCAATGCTCCACACCTGCGCCTTNTGAGATGTTCT 829
Qy      80      uCysAspSerProTyrGlnLeuLeuSerAlaPheAspPheIleLysAsnSerGlyG 100
Db      830      GTGTGATTCCTCATATCACTATTATTTGTGACGATTTGATTTATTAATAATCTGACAA 889

```

```

Qy 100 ngulalaserpheneticlertrphtglaaspeerprophiovalprovalproglule 120
Db 890 AGAAGCATCTTTCATGATATGACAGAGGATAGCCACCTCATCTTCTGACTGAACT 949
Qy 120 uSerThrAspThrValIleAsnValIleThrAsnMetThrThrIleGlnSerLeuPh 140
Db 950 CTCMAAGACACCTGTTAAATGATGATCACTAATATATGACAAACCACTCCAGACTCTT 1009
Qy 140 eProAsnLeuGlnValPheProAlaLeuGlnAsnHisAspTyrTrpProGlnAspGln 160
Db 1010 TCCAAATCTCCAGGTTTCCCTGGCTGGGTTAAATCATGACTATTTGGCCACAGATCACT 1069
Qy 160 uSerValValThrSerIleValTyrAsnAlaValAlaAsnLeuTrpLysProTyrLeu 180
Db 1070 GCCTTATGTCACCACTAAAGTTCATGACATGACATGCAAACTCTTGGAACCATGCTTGA 1129
Qy 180 pglugluvalalaserthrleuarglyglypheTyrserGlnLysValThrThrAs 200
Db 1130 TGAAGAAAGCTTATGATCTTTAAGAAAGGTGGTTTTTATTCACAGAAAGTTACACATA 1189
Qy 200 nProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrTyrGlyProAsnIleMetTh 220
Db 1190 TCCAAACTTATGATGATCATGCTATNACACAACTTGTACTACGCCCCCAATATATATGAC 1249
Qy 220 rLeuAsnLysThrAspProAlaAsnGlnPheGluTrpLeuGlnuSerThrLeuAsnAsn 240
Db 1250 ACTGAACAAAGCTATACCCACGCAACGTTTGAATGGCTAGAAAGTTCATTTGAACAATCTC 1309
Qy 240 rGlnGlnAsnLysGlnLysValTyrIleIleAlaHisValProValGlyTyrLeuProse 260
Db 1310 TCAGCAGAAATAGAGAGAGAGGTATATCATATGACATGTTCCAGTGGGGTATCTGCCATC 1369
Qy 260 rSerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGlnLysLeuIleAspIlePheG 280
Db 1370 TTCACAGAAATCATCACCAATGAGAGAAATCTATATATGAGAAATGATGATATTTTCA 1429
Qy 280 nLysTyrSerAspValIleAlaGlnPheTyrGlyHisThrHisArgAspSerIleMe 300
Db 1430 AAATATCAGTATGATCTTTCAGAGACAAATTTATGACACACTACACAGACACACATTTAT 1489
Qy 300 tValLeuSerAspLysLysGlySerProValAsnSerLeuPheValAlaProAlaValTh 320
Db 1490 GGTTCCTTCAGATTAAGAAAGGAACTCAGTAATTTCTTTGTTGGCTCCTGCTGTATAC 1549
Qy 320 rProValLysSerValLeuGlnLysGlnThrAsnAsnProGlyIleArgLeuPheGlnT 340
Db 1550 ACCAGTGAAGAGTCTTTTAGAAAAACAGACCAACATCTGGTATTCAGACTGTTTCAGTA 1609
Qy 340 rAspProArgAspTyrTyrLysLeuAspMetLeuGlnTyrTyrLeuAsnLeuThrGluAl 360
Db 1610 TGATCCTCGTATATTAATTAATTTATGATATGTTTCAGATTAATTTGATGACAGAGGC 1669
Qy 360 aAsnLeuLysGlyLysSerIleTyrLysLeuGlnTyrIleLeuThrGlnThrTyrAspI 380
Db 1670 GAATCTAAAGGAGAGAGTCCATCTCGAAGCTGATATATCTGACCCAGACCTACGACAT 1729
Qy 380 eGluAspLeuGlnProGlnuSerLeuTyrGlyLeuAlaLysGlnPheThrIleLeuAsp 400
Db 1730 TGAAGATTTGACGCGGAAAGTTATATGATTTGCTTGAACAAATTTCAATCTTAGACAG 1789
Qy 400 rLysGlnPheIleLysTyrTyrAsnTyrPhePheValSerTyrAspSerValThrCy 420
Db 1790 TTAGCAGATTAATAAATCAATCAATCTTTGTTGATATATACAGCAGCTGTAACATG 1849
Qy 420 sAspLysThrCysLysAlaPheGlnIleCysAlaAlaMetAsnLeuAspAsnIleSerT 440
Db 1850 TGATTAAGACATGTAAGGCTTTTCAGATTTGTCATTAATGATCTTGTATATATTTCTTA 1909
Qy 440 rAlaAspCysLeuLysGlnLeuTyrIleLysHisAsnTyr 453
Db 1910 TGCAGATTTGCTCAACAGCTTTATATTAAGCAACAAATTAC 1949

```

```

AA161110
ID AA161110 standard; cDNA; 1873 BP.
AC AA161110;
XX 22-OCT-2001 (first entry)
DE Human polynucleotide SEQ ID NO 5099.
XX Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
XX peripheral nervous system; neuropathy; central nervous system; CNS;
XX Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
XX amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
XX chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
XX leukaemia; ss.
XX Homo sapiens.
XX WO20015312-A1.
XX 26-JUL-2001.
XX 26-DEC-2000; 2000WO-US034263.
XX 23-DEC-1999; 99US-00471275.
XX 21-JAN-2000; 2000US-00488725.
XX 25-APR-2000; 2000US-00552317.
XX 20-JUN-2000; 2000US-00598042.
XX 19-JUL-2000; 2000US-00620312.
XX 03-AUG-2000; 2000US-00653450.
XX 14-SEP-2000; 2000US-00662191.
XX 19-OCT-2000; 2000US-00693036.
XX 29-NOV-2000; 2000US-00727344.
XX (HYSE-) HYSSEQ INC.
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
XX Wang J, Wang Z, Wehman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;
XX Zhou F, Goodrich R, Drmanac RT;
XX WPI; 2001-442253/47.
XX P-PSDB; AAM41954.
XX Novel nucleic acids and polypeptides, useful for treating disorders such
XX as central nervous system injuries.
XX Claim 1; SEQ ID NO 5099; 10078bp; English.
XX The invention relates to human nucleic acids (AA157798-AA161369) and the
XX encoded polypeptides (AAM38642-AAM42213) with nootropic,
XX immunosuppressant and cytostatic activity. The polynucleotides are useful
XX in gene therapy. A composition containing a polypeptide or polynucleotide
XX of the invention may be used to treat diseases of the peripheral nervous
XX system, such as peripheral nervous injuries, peripheral neuropathy and
XX centralised neuropathies and central nervous system diseases, such as
XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
XX utilisation of the activities such as: immune system suppression,
XX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,
XX assays for receptor activity, arthritis and inflammation, leukaemia and
XX C.N.S disorders. Note: The sequence data for this patent did not form
XX part of the printed specification
XX
SQ Sequence 1873 BP; 596 A; 359 C; 335 G; 583 T; 0 U; 0 Other;
XX
Alignment Scores:
Pred. No.: 2,12e-204 Length: 1873
Score: 2223.00 Matches: 416
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 91.59% Indels: 0
DB: Gaps: 0

```

US-09-823-119b-1 (1-453) x AA161110 (1-1873)

QY 38 GlycinePheThrPheValThrAspLeuHisLeuAspProThrTyrHisIleThrAspAsp 57
 Db 303 GGACAGATTGGCAATGAGTACGACTTACACTTACACCTTACTTACACATCACAGATGAC 362
 QY 58 HistidineValCysAlaSerSerLeuGlyValAlaSerAspProGlyProPheGly 77
 Db 363 CACCAAAAGTGTGCTTCAATCTAAAGTGCAGAAATGCTCCAACTGAGCCCTTTTGA 422
 QY 78 AsparagineCysAspSerProTyrGlnLeuIleLeuSerAlaPheAspPheIleLeuAsn 97
 Db 423 GATGTCGTGTGATTTCCATATCACTAATTTTGTGACATTTGATTTATTTAAAT 482
 QY 98 SerGlyGlnGluAlaSerPheMetIleThrThrGlyAspSerProProHisValProVal 117
 Db 483 TCTGGACAGAGAGATCTTTCATGATATGACAGGGAGATGCCACCTCATGTCTGTGA 542
 QY 118 ProGluLeuSerThrAspThrValIleAsnValIleThrAspMetThrThrIleGln 137
 Db 543 CTTGAACTCTCAACAGACACTGTTATTAATGTGATCTAATATGACAAACCAATCCAG 602
 QY 138 SerLeuPheProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrTyrProGln 157
 Db 603 AGTCTCTTCCAAATCTCCAGGTTTCCCTGCGGTGATATGATGATATGGCCACAG 662
 QY 158 AsparagineSerValIleThrSerLeuValTyrAsnAlaValAlaAsnLeuTyrPro 177
 Db 663 GATCACTGTCTGTAGTACACAGTAAAGTGTACATCAGATGACAACTCTGAAACCA 722
 QY 178 TryptophanGluValIleSerThrLeuArgLeuGlyPheTyrSerGlnLeuVal 197
 Db 723 TGGCTAATGAAAGACTATTTAGTACTTTAAGAAAGGTGTTTATTACAGAAAGTT 782
 QY 198 ThrThrAsnProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrGlyProAsn 217
 Db 783 ACAACTAATCCAAACTTAGATCATGCTAAACAAACTGTGCTAGGCGCAAT 842
 QY 218 IleThrThrLeuAsnLeuTyrThrAspProAlaAsnGlnPheGluTyrPheLeuSerThrLeu 237
 Db 843 ATAATGACACTGAAACAGACTGACCCAGCCAAAGTTGATGCTGAAAGATCACTTTG 902
 QY 238 AsnAsnSerGlnGlnAsnLeuGlyValTyrIleIleAlaHisValProValGlyTyr 257
 Db 903 AACCACTCTCAGCAGATTAAGAGAAAGTGTATCTATGACACATGTTCCAGTGGGTAT 962
 QY 258 LeuProSerSerGlnAsnIleThrAlaMetArgGluTyrTyrAsnGluLeuLeuAsp 277
 Db 963 CTGCATCTTCACAGAACATCACAGCAATGAGAAATATATATGAGAAATGATGAT 1022
 QY 278 IlePheGlnLeuTyrSerAspValIleAlaGlyGlnPheTyrGlyHisThrHisArgAsp 297
 Db 1023 ATTTTAAAAAATACATGATGATGATGACGAGAAATTTATGACACACTCACAGAGAC 1082
 QY 298 SerIleMetValLeuSerAspLeuGlySerProValAsnSerLeuPheValAlaPro 317
 Db 1083 AGCATTTATGTTCTTTAGATTAAGAAAGAGTCCAGTAAATCTTTGTTGTGGCTCCT 1142
 QY 318 AlaValThrProValIleSerValLeuGluLeuGlnThrAsnAsnProGlyIleArgLeu 337
 Db 1143 GCTGTACACACAGTGAAGAGTGTGAAAAAACAAGCAACCAATCTCGATACAGACTG 1202
 QY 338 PheGlnTyrAspProAspAspTyrLeuLeuLeuAspMetLeuGlnTyrTyrLeuAsnLeu 357
 Db 1203 TTTTCAGATATATCTCTGATTAATAATTAATGATATGTTGACGATTTACTTGAATCTG 1262
 QY 358 ThrGluAlaAsnLeuLeuGlyGluSerIleTyrPheLeuGluTyrIleLeuThrGlnThr 377
 Db 1263 ACAGAGCGAATCTAAAGGAGAGTCAATCGAAGCTGAGATATCTGACCCAGACC 1322
 QY 378 TyrAspIleGluLeuLeuGlnProGluSerLeuTyrGlyLeuAlaLeuGlnPheThrIle 397

Db 1323 TACGACATGAGATTGTCAGCCGGAAGTTATATGATATAGTAAACATTTACATC 1382
 QY 398 LeuAspSerLeuGlnPheIleLeuTyrTyrAsnTyrPhePheValSerTyrAspSerSer 417
 Db 1383 CTAGACAGTAAAGATTTATTAATAATCTACAAATTAATCTTTGTGTGATATGACAGAGT 1442
 QY 418 ValThrCysAspLeuThrCysLeuAlaPheGlnIleCysAlaIleMetAsnLeuAspAsn 437
 Db 1443 GTACATGTGATTAAGACATTAAGGCTTTCAAGATTTTGCAATTTATGATCTTGATAT 1502
 QY 438 IleSerTyrAlaAspCysLeuLeuGlnLeuTyrIleLeuHisAsnTyr 453
 Db 1503 ATTTCTATGACATTTGCTCAACAGCTTATATTAAGCACATTAAC 1550
 RESULT 11
 AA159324
 ID AA159324 standard; cDNA; 1874 BP.
 XX
 AC AA159324;
 XX
 DT 22-OCT-2001 (first entry)
 XX
 DE Human polynucleotide SEQ ID NO 1527.
 XX
 KW Human; nontropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW atropotropic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200153312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26-DEC-2000; 2000MO-US034263.
 XX
 PR 23-DEC-1999; 99US-00471275.
 PR 21-JAN-2000; 2000US-00488725.
 PR 25-APR-2000; 2000US-00552317.
 PR 20-JUN-2000; 2000US-00598042.
 PR 19-JUL-2000; 2000US-00620312.
 PR 03-AUG-2000; 2000US-00653450.
 PR 14-SEP-2000; 2000US-00662191.
 PR 19-OCT-2000; 2000US-00693036.
 PR 29-NOV-2000; 2000US-00727344.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QH;
 PI Zhou P, Goodrich R, Dirmanc RT;
 XX
 WP1; 2001-442253/47.
 P-PSDB; AAM40168.
 XX
 PT Novel nucleic acids and polypeptides, useful for treating disorders such
 as central nervous system injuries.
 XX
 PS Claim 1; SEQ ID NO 1527; 10078pp; English.
 XX
 CC The invention relates to human nucleic acids (AA157798-AA161369) and the
 CC encoded polypeptides (AAM38642-AAM42213) with nontropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression.

CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukemias and
 CC C.N.S disorders. Note: The sequence data for this patent did not form
 CC part of the printed specification

XX Sequence 1874 BP; 596 A; 357 C; 334 G; 587 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	Length:	Matches:	1874
Score:	2.12e-204	2223.00	416
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	91.59%	Indels:	0
DB:	4	Gaps:	0

US-09-823-119b-1 (1-453) x AA159324 (1-1874)

QY 38 G1VGINPHERPHISVALTHIRASPLEUHIISLEUASPPROTHYRHSILETHIRASASP 57
 DB 303 GGACAGTTTGGCATGTGACTGACTTACCTTAACCTTACTTACACATACAGATGAC 362
 QY 58 HIRTHIRYVALCYBALASERISERISGLYALASASLASERASPROGLYPROPHICLY 77
 DB 363 CACACAAAAGTGTGCTTCACTTAAGGTCAATGCTTCAACCTGCGCTTTTGA 422
 QY 78 ASYVALLEUCYASAPSERPROTYRGINLEUILEUSERIALAPHEASPPHEILEYASN 97
 DB 423 GATGTTCTGTGTGATTCCTCATATCACTTAATTTGTGAGATTTGATTTATTAATAAT 482
 QY 98 SERGLYINGIUALASERPHEMETIETRTHIRGLYASPSERPROPHISVALPROVAL 117
 DB 483 TCTGGACAAAGAGCATCTTTATGATATGACAGAGGATGACCACTCATGTTCTGTA 542
 QY 118 PROGLUSESERTHIRASPTHIRVALILEASNAVALIETHIRASMECTHIRTHIRILEGIN 137
 DB 543 CCTGACATCTTCAACAGACACTGTTATTAATGATGACTTAATATGACACACCATCAG 602
 QY 138 SERLEUPHEPROANLEUGINVALPHEPROALIEUGIYASPHISASPTYRTPROGIN 157
 DB 603 AGTCTCTTCCAAATCTCCAGAGTTCCTTCGCTGGGTATCATGACTATTGCGCCACAG 662
 QY 158 ASPGINLEUSERVALIETHIRSERISVALIETHIRASNAVALIETHIRASLEUTRIPRO 177
 DB 663 GATCACTGCTGTGATGACAGGATGACAGGATGACAGGATGACAGGATGACAGGATGAC 722
 QY 178 TRIPLEASPGIUGIUALIETHIRSERTHIRLEUARGIYGLYPHERYSERGINLYSVAL 197
 DB 723 TGGCTAGATGAGAGAGCTATTAGTACTTTAAGAAAGTGTGTTTATTCACAGAAAGTT 782
 QY 198 THIRTHIRASPROANLEUARGILEIETHIRASLEUANTHIRANLEUYRTRYGLYPROASN 217
 DB 783 ACAACTAATCCAAACCTTAGATCATGCTTAACCAACAACTGTACTAGCGCCCAAT 842
 QY 218 ILEETHIRLEUASNYSTHIRASPROALASNGINPHEGIUTRIPLEUGIUSERTHIRLEU 237
 DB 843 ATATATGACATGAAACAGACTGACCCCAACCAAGTTTGAATGGCTGAAAGATCATTTG 902
 QY 238 ASNAASERGINASNIASNYSGIULYSEVALIETHIRLEIETHIRASVALPROVALIETHIR 257
 DB 903 AACCACTCTGACGAATTAAGAGAGGTATATCATAGACATGTTCCAGTGGGGAT 962
 QY 258 LEUPROSERISERGINASNIETHIRALAMECARGIUTRYRANGLIULYSEUILEASP 277
 DB 963 CTGCACTCTTCAAGAACATCAAGCAATGAGAAATCTATTAATGAGAAATTAATGAT 1022
 QY 278 ILEPHEGINLYSTYRSEASPPVALIETHIRLEIETHIRASNYSTHIRASNYSTHIRAS 297
 DB 1023 ATTTTCAAAAATACAGATGATCATGTGACAGACAAATTTTATGACACACTCAAGAAC 1082
 QY 298 SERILEMETVALIETHIRASPPYLYSGIYSEPROVALASERISLEUPHEVALIETHIR 317
 DB 1083 AGCATTTATGTTCTTTTCAGATTAAGAAAGAGTCCAGTAATTTCTTTGTTGCTCTCT 1142

QY 318 A1AVALTHIRPROVALIETHIRSERVALIETHIRLEUGIULYSGIINTHIRASNAANPROGLIYLEARGLEU 337
 DB 1143 GCTGTTACACAGTGAAGAGTGTGTTTGAAGAAACAGACCAACATCTGTTATCAGACTG 1202
 QY 338 PHEGINLYRASPPOARGASPTYRISYLSLEUASPPHEIETHIRYRILEUASNIETHIR 357
 DB 1203 TTTTCAGTATGATCTGATGATTAATAATATGATGATGATGATGATGATGATGATGATGAT 1262
 QY 358 THIRGLIALASNIETHIRYSGIULYSEUILEIETHIRLEUGIULYRILEUETHIRINETHIR 377
 DB 1263 ACAGAGCGAATTTAAAGAGAGTGCATCTGAGAGCTGAGATATCCGACCAACACC 1322
 QY 378 TYRASPIIETHIRASPPHEIETHIRYRILEUASNIETHIRYRILEUASNIETHIRYRILE 397
 DB 1323 TACGACATTAAGATTTGACAGCCGGAAGTTTATAGATTTAGCTTAACATTAACATTTACATC 1382
 QY 398 LEUASPSERISYSGINPHEIETHIRYRILEUASNIETHIRYRILEUASNIETHIRYRILE 417
 DB 1383 CTGACAGTAAAGAGTTTATTAATAATCAATTAATTAATTAATTAATTAATTAATTAATTA 1442
 QY 418 VALTHIRCYASPPYRTHIRCYLYSVALIETHIRINETHIRYRILEUASNIETHIRYRILE 437
 DB 1443 GTAAACATGATTAAGATGATTAAGAGCTTCAATTTGTGCAATTTATGAAATCTTGAATAT 1502
 QY 438 ILESERIETHIRALASPPCYLSLEULYSGINLEUETHIRILEYSHISASNTYR 453
 DB 1503 ATTTCTTACAGATTTGCTTCAACACCTTTATTAATTAAGCAATTTAC 1550

RESULT 12
 ADL62954
 ID ADL62954 standard; DNA: 2049 BP.
 AC ADL62954;
 XX 20-MAY-2004 (first entry)
 DT
 XX
 DE Human ovarian cancer DNA marker #21166.
 XX
 KW Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.
 OS Homo sapiens.
 PN W0200170979-A2.
 XX
 PD 27-SEP-2001.
 XX
 PF 21-MAR-2001; 2001WO-US009126.
 XX
 PR 21-MAR-2000; 2000US-0191031P.
 PR 25-MAY-2000; 2000US-0207124P.
 PR 15-JUN-2000; 2000US-0211940P.
 PR 07-JUL-2000; 2000US-0216820P.
 PR 25-JUL-2000; 2000US-0220661P.
 PR 21-DEC-2000; 2000US-0257672P.
 XX
 PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
 XX
 PI Lee J, Lillie J;
 XX WPI; 2001-611502/70.
 DR
 XX Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
 PT cancer cells as compared to their normal non-cancerous ovarian cells are
 PT used to characterize stage, grade, histological type of ovarian cancer.
 XX
 XX Disclosure; SEQ ID NO 21166; 106pp; English.
 XX
 CC The invention relates to nucleic acid markers which are overexpressed in
 CC ovarian cancer cells as compared to their expression in normal (i.e. non-
 CC cancerous) ovarian cells. The invention also relates to polypeptides
 CC encoded by the markers, antibodies that selectively bind to the
 CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk

PN WO200188188-A2.
 XX 22-NOV-2001.
 XX 18-MAY-2001; 2001WO-JP004192.
 XX 18-MAY-2000; 2000JP-00145977.
 PA (UNIV-) UNIV NIHON SCHOOL JURIDICAL PERSON.
 PI Ishikawa K, Asai S, Takahashi Y, Nagata T, Ishi Y;
 DR WPI; 2002-034733/04.
 PT P-PSDB; ABB57183.
 PT Examining the ischemic condition (e.g. occlusive ischemia) by measuring
 PT expression levels of particular genes defined in the specification or by
 PT determining the expression profile of a gene group comprising these
 PT genes.
 XX
 PS Claim 2; Page 1248-1251; 2690pp; English.
 CC The present invention describes a method for examining ischaemic
 CC conditions, comprising measuring the expression levels of particular
 CC genes (I) in a test sample or determining the expression profile of a
 CC gene group in the sample comprising genes selected from (I). The method
 CC is useful for examining the ischaemic condition (e.g. compressive
 CC ischaemia, occlusive ischaemia or vasospastic ischaemia) by measuring
 CC expression levels of particular genes (ABI99202 to ABI9912, encoding the
 CC protein sequences in ABB57020 to ABB57374) or by determining the
 CC expression profile of a gene group comprising these genes. The expression
 CC levels or expression profiles produced by these genes are used as an
 CC indicator when screening for ischaemic condition-improving drugs or
 CC therapeutics for ischaemic diseases. ABI9913 and ABI9914 represent PCR
 CC primers for a mouse ischaemic condition related sequence, which are used
 CC in the exemplification of the present invention
 CC
 SQ Sequence 1758 BP; 493 A; 415 C; 386 G; 462 T; 0 U; 2 Other;
 Alignment Scores:
 Pred. No.: 2,098-178 Length: 1758
 Score: 1953.50 Matches: 359
 Percent Similarity: 88.96% Conservative: 44
 Best Local Similarity: 79.25% Mismatches: 47
 Query Match: 80.49% Indels: 4
 DB: 6 Gaps: 1

US-09-823-119B-1 (1-453) x ABI99482 (1-1758)

QY 1 MetAlaLeuValAlaGAlaLeuValCysCysLeuLeuThraAlaThrHisCysArgSerGly 20
 DB 93 ATGGCGTGGCGGCACTCTTGTGCTGCTACTGCTGCTGCTGCTGCGCCCGGCG 152
 QY 21 LeuGlyLeuProValAlaProAlaGlyGlyArgAsnProProAlaIleGlyGlnPhe 40
 DB 153 CTCGGGGGGCCCCCTGGCGCGCGGCG-----GATCCGCCGCCAGCTGTGGGCGAGTTT 203
 QY 41 TrpHisValThrAspLeuHisLeuAspProThrTyrrHisIleThrAspAspHisThrIys 60
 DB 204 TGGCAGCGTAGCTACTGATCTAGACCCCTACTTACCACTTACAGATGACCGTACCAAG 263
 QY 61 ValCysAlaSerSerIysGlyAlaAsnAlaSerAsnProGlyProPheGlyAspValLeu 80
 DB 264 GTGTGTGCTTATCATTAAGGCGCAAAATGCTTCAACCTTGAGCTTTCTGGAGATGTCTG 323
 QY 81 CysAspSerProTyrrGlnLeuIleLeuSerAlaPheAspPheIleIysAsnSerGlyGln 100
 DB 324 TGTGACTCTTCATATCACTTATTTGTCAACCTTTGATTTTATTAAGATTCAGAGCAA 383
 QY 101 GluAlaSerPheMetIleTrpThrGlyAspSerProProHisValProValProGlnLeu 120
 DB 384 GAACATCTTTCAATGATATGACAGGGGATAGCCACCTCATGTGCCAGTACTGAATCTC 443

QY 121 SerThrAspThrValIleAsnValIleThrAsnMetThrThrThrIleGlnSerLeuPhe 140
 DB 444 TCACACAGGCAACCGGATTAAGAGTATGATCACTTACATGACATATGATCTCCAGAACCTGTTT 503
 QY 141 ProAsnLeuGlnValPheProAlaLeuGlyAsnHisAspTyrrTrpProGlnAspGlnLeu 160
 DB 504 CCAAACTCCAGGTTTTCTCTGCACTGGCAATCATCATCTACCTGGCCACAGGACCACTG 563
 QY 161 SerValAlaThrSerIysValTyrrAsnAlaValAlaAsnLeuTrpIleProTrpLeuAsp 180
 DB 564 CCATATGCTACCGGTAAAGTGTACGTGTGTGCTGTGCTGGAATCTGAGTGGCT 623
 QY 181 GluGlnAlaIleSerThrLeuArgIysGlyGlyPheTyrrSerGlnIysValThrThrAsn 200
 DB 624 GAAGAACCTTATGACCTTTTAAAGAAAGTGTGTTTACTCAGAGAAAGTTGCAAGTAT 683
 QY 201 ProAsnLeuArgIleIleSerLeuAsnThrAsnLeuTyrrGlyProAsnIleMetThr 220
 DB 684 CCAAGCTTGAGGATCATTTAGCTTAAACAACTTGTACTATGCGCCAAACATCATGACC 743
 QY 221 LeuAsnIleThrAspProAlaAsnGlnPheGluTrpLeuGlnIleSerThrLeuAsnSer 240
 DB 744 CTGAACAAAGCAGACCCAGCAAAATCAAGTTGAATGCTGGAATAATACATCAACAGCTCT 803
 QY 241 GlnGlnAsnIysGlnIysValTyrrIleAlaHisValProValGlyTyrrLeuProSer 260
 DB 804 CTATGCAATTAAGAGAAAGATATCATAGCCGATTTCCAGTGGGCTATCTCCCTTAT 863
 QY 261 SerGlnAsnIleThrAlaMetArgGluTyrrTyrrAsnGlnIysLeuIleAspIlePheGln 280
 DB 864 GCAACTACACCCCGCGGAATAGGCACTATCATATATAGAACTGCTGATATTTTCAGA 923
 QY 281 LysTrpSerAspValIleAlaGlyGlnPheTyrrGlyHisThrHisAspAspSerIleMet 300
 DB 924 AGATACAGCTCCGATTTGGCGGCACTTCTATGCGCACCCATTAAGACAGCTTATG 983
 QY 301 ValLeuSerAspIysGlySerProValAsnSerLeuPheValAlaProAlaValThr 320
 DB 984 GTCCCTTTCAGTATTAAGAGGAAATCCACTCATTTCTGTGTGGGCACTGCGCTTACA 1043
 QY 321 ProValIysSerValLeuGlnIysGlnThrAsnAsnProGlyIleArgLeuPheGlnTyrr 340
 DB 1044 CCAATGAAAGAGATTATTAACAAAGAGAACCAACCAATCCCGGTGTCCTATTTTCACTAC 1103
 QY 341 AspProArgAspTyrrIysLeuLeuAspMetLeuGlnTyrrTyrrLeuAsnLeuThrGlnAla 360
 DB 1104 AAGCTGTGATTTACATTCATGTCGACATGTCATGTCATTTGAACTTGAACTTGACAGAAAGC 1163
 QY 361 AsnLeuIysGlyGlnSerIleTrpIysLeuGlnTyrrIleLeuThrGlnThrTyrrAspIle 380
 DB 1164 AATCTTAAGAGAAATCCAACTGACATTTGAGATGTCTTGACTCAGGCTTACAGTGT 1223
 QY 381 GluAspLeuGlnProGlnSerLeuTyrrGlyLeuAlaIysGlnPheThrIleLeuAspSer 400
 DB 1224 GCAGATCTGACGCAAAAGATATATATGCTTACTGATCAGCAATTTTGCAACCAAGACAGC 1283
 QY 401 LysGlnPheIleIysTyrrTyrrAsnTyrrPhePheValSerTyrrAspSerSerValThrCys 420
 DB 1284 AAGCAGTCTCGAAATCTACATTAATTTGTGTGATTAATGACACAGGCAACTGT 1343
 QY 421 AspIleThrCysIysAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyrr 440
 DB 1344 GACCAAGATTTGAAGACCTTACAGGTGTGTGCAATTTGATATCTTGTATAGCATCTCTAT 1403
 QY 441 AlaAspCysLeuIysGlnLeuTyrrIleIysHisAsnTyrr 453
 DB 1404 GATGATTCCTTAAACAGCA-TTATATTAACACAGTAC 1441
 RESULT 14
 AAD21344 standard; cDNA; 1095 BP.
 ID AAD21344
 XX AAD21344;
 AC AAD21344;

Db 814 AATCTAAGGAGAGTCCATCTGAGAGCTGAGATATCTGACCCAGACCTAGACAT 873
 Qy 381 GluapleuGlnProGlnSerLeuTyrGlyLeuAlaIleValGlnPheThrIleLeuAspSer 400
 Db 874 GAAAGTTTGACGCCGGAAGTTTATATGATTAAGCTTAAACAATTTACATCTAGACAGT 933
 Qy 401 LysGlnPheIleIleTyrTyrAsnTyrPhePheValSerTyrAspSerSerValThrCys 420
 Db 934 AAGCATTTATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 993
 Qy 421 AspLeuTyrCysValAlaPheGlnIleCysAlaIleMetAsnLeuAspAsnIleSerTyr 440
 Db 994 GATTAAGACATGATTAAGACCTTTCAGATTTGTGCAATTAATTAATTAATTAATTTCTAT 1053
 Qy 441 AlaAspCysLeuLeuGlnLeuTyrIleIleYshIleAsnTyr 453
 Db 1054 GCAGATTGCTCAACAACGCTTATATTAAGCAACATTAAC 1092
 RESULT 15
 ID AAA02374
 ID AAA02374 standard; cDNA, 728 BP.
 AC AAA02374;
 XX 19-MAY-2000 (first entry)
 DE Human colon cancer cell line polynucleotide sequence SEQ ID NO:2365.
 XX
 XX Human; colon cancer; tumour; diagnosis; gene expression product; probe;
 KM detection; cancerous state; metastasis; identification; breast cancer;
 KM oestrogen receptor-positive breast cancer; therapy;
 KM oestrogen receptor-negative breast cancer; lung cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN MO958675-A2.
 XX 18-NOV-1999.
 XX 13-MAY-1999; 99MO-US010602.
 XX 14-MAY-1998; 98US-0085426P.
 PR 15-MAY-1998; 98US-0085537P.
 PR 15-MAY-1998; 98US-0085696P.
 PR 21-OCT-1998; 98US-0105234P.
 PR 27-OCT-1998; 98US-0105877P.
 PA (CHIR) CHIRON CORP.
 PA (HYSE-) HYSEQ INC.
 XX
 PI Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;
 PI Reinhard C, Giese K, Randazzo F, Kennedy GC, Pot D, Kaasam A;
 PI Lamson G, Dmanac R, Crkvenjakov R, Dickson M, Dmanac S, Labat I;
 PI Leshkowitz D, Kita D, Garcia V, Jones LW, Stache-Crain B;
 XX
 DR WPI; 2000-126369/11.
 XX
 PT Polynucleotide library used to determine cancerous states of mammalian
 cells.
 PS Claim 1; Page 940; 1097pp; English.
 XX
 CC AAA00010 to AAA02716 represent polynucleotides isolated from cDNA
 CC libraries constructed from human colon cancer cell lines. The present
 CC invention also describes a method of detecting differentially expressed
 CC genes correlated with a cancerous state of a mammalian cell, comprising
 CC detecting at least one differentially expressed gene product in a test
 CC sample derived from a cell suspected of being cancerous, where detection
 CC of the differentially expressed gene product is correlated with a
 CC cancerous state of the cell from which the test sample was derived. The
 CC polynucleotide sequences can be used in a method for detecting
 CC differentially expressed genes correlated with a cancerous state of a
 CC mammalian cell. The polynucleotides can also be used as probes for

CC detecting and mapping related genes. They can be used in diagnosis and
 CC prognosis of diseases and disorders (e.g. identification of pre-
 CC metastatic or metastatic cancerous states, stages of cancer, or
 CC responsiveness of cancer to therapy). This is particularly for breast
 CC cancer, oestrogen receptor-positive breast cancer, oestrogen receptor-
 CC negative breast cancer, lung cancer, and colon cancer
 XX

SQ Sequence 728 BP; 240 A; 155 C; 139 G; 189 T; 0 U; 5 Other;

Alignment Scores:

Pred. No.:	Length:	Matches:	Conservative:
Score:	4.9e-107	728	230
Percent Similarity:	1209.00		
Best Local Similarity:	98.71%		
Query Match:	49.81%		
DB:	3	Gaps:	0

US-09-823-119B-1 (1-453) x AAA02374 (1-728)

Qy	110	AspSerProProHisValProValProGlnLeuSerThrAspThrValIleAsnValIle	129
Db	28	GATAGCCACCTCAAGTTCTCTGATCACTCAACAGACGATTAATTAATGATATC	87
Qy	130	ThrAsnMetThrThrThrIleGlnSerLeuPheProAsnLeuGlnValPheProAlaLeu	149
Db	88	ACTAATATGACAAACACATCAAGATCTCTTCCAAATCTCCAGTTTCCGCGCTG	147
Qy	150	GlyAsnHisAspTyrTyrProGlnAspGlnLeuSerValValThrSerValTyrAsn	169
Db	148	GATATCATGATCAATGATGAGCAAGATCAACTGCTTATGACCACTTAAGTATCAAT	207
Qy	170	AlaValAlaAsnLeuTyrPheProTyrLeuAspGlnIleIleSerThrLeuArgLys	189
Db	208	GCAGTAGCAAACTCTGAAACCATGCTAGATGAAGATTAATTAATTAAGGAAA	267
Qy	190	GlyGlyPheTyrSerGlnLysValThrThrAsnProAsnLeuArgIleIleSerLeuAsn	209
Db	268	GGTGGTTTATTAATCAAGAAAGTTACAACTATCAACCTTGAATCAATCAAGTAAAC	327
Qy	210	ThrAsnLeuTyrTyrGlyProAsnIleMetThrLeuAsnLysThrAspProAlaAsnGln	229
Db	328	ACAAACTTGTATCAAGCCCAAAATATATATGACACTGAACAAGACTGACCCAGCAACAG	387
Qy	230	PheGlnTyrLeuGlnSerThrLeuAsnAsnSerGlnIleAsnLysGlyValTyrIle	249
Db	388	TTTGAATGCTAGAAAGTATTAATTAATTAATTAATTAATTAATTAATTAATTAAT	447
Qy	250	IleAlaHisValProValGlyTyrLeuProSerSerGlnAsnIleThrAlaMetArgLys	269
Db	448	ATGACACATGTTCCAGTGGGATATCTCCATCTTCAAGAAATCAACGACATAGAGAA	507
Qy	270	TyrTyrAsnGlnLysLeuIleAspIlePheGlnLysTyrSerAspValIleAlaGlyGln	289
Db	508	TACTATATAGAAATGATATGATATTTTCAAAAATACAGATGATGATGATGATGATG	567
Qy	290	PheTyrGlyHisThrHisArgAspSerIleMetValLeuSerAspLysGlySerPro	309
Db	568	TTTATGACACATCAACAGACAGACATTAATGATTTTCAAGTAAAGAAAGATGCA	627
Qy	310	ValAsnSerLeuPheValAlaProAlaValThrProValLysSerValLeuGlnLysGln	329
Db	628	GTAATTTCTTTGTTTGCGCTCTCGCTTACACCACTGAAGATGTTTATGAAAAACAG	687
Qy	330	ThrAsnAsnProGlyIleArgLeuPheGlnTyrAspPro	342
Db	688	ACCAACATATCTGATCAAGATGATGATGATGATGATGATGATGATGATGATGATG	726

Search completed: April 5, 2005, 13:24:41
 Job time : 654 secs

THIS PAGE BLANK (USPTO)